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resumo 
 
 
A proteína Gαo é uma das subunidades alfa da família das proteínas G 
heterotriméricas, proteínas envolvidas na transdução de sinais a partir 
recetores membranares. Gαo é principalmente expressa nos neurónios, 
encontrando-se localizada ao longo da membrana plasmática, incluindo nos 
cones de crescimento dos neurónios, onde também se encontra a Proteína 
Precursora de Amilóide de Alzheimer (PPA), uma proteína membranar com um 
papel central na doença de Alzheimer. Algumas funções semelhantes já foram 
atribuídas às duas proteínas, incluindo papéis na diferenciação e migração 
celular. A ligação da PPA à Gαo já foi descrita, o que pode indicar que a PPA 
modula as suas funções através da ligação e ativação da Gαo. Também já foi 
demonstrado que uma das vias pela qual a Gαo leva à neuritogénese é a 
ativação do transdutor de sinal e ativador da transcrição 3 (STAT3). A Gαo liga-
se ao domínio C-terminal da PPA, nos aminoácidos His657-Lis676, que 
pertencem a uma região hidrofóbica imediatamente a jusante do sorting motif  
653YTSI656. Isto leva a crer que a ligação entre a PPA e a Gαo pode ser mediada 
pela fosforilação da PPA no resíduo Serina 655 (S655). Assim, a fosforilação 
da PPA poderia influenciar a ativação da Gαo e consequente sinalização via 
STAT3. 
Neste trabalho, nós estudámos os efeitos da fosforilação da PPA e ativação da 
Gαo na interação funcional da PPA/Gαo. Isto foi analisado por cotransfeção de 
células de neuroblastoma humano não diferenciadas (SH-SY5Y) com PPA-
GFP selvagem ou fosfomutante (PPA com a S655 constutivamente fosforilada 
ou desfosforilada) e com a Gαo selvagem ou  Gαo constutivamente ativa. As 
células foram sujeitas a ensaios de imunofluorescência e vários parâmetros 
foram analisados, tais como a colocalização subcelular da PPA e da Gαo, o 
número de prolongamentos celulares e o seu comprimento, e a intensidade da 
STAT3 no núcleo. Toda a análise quantitativa feita nas microfotografias foi 
realizada no software Fiji (ImageJ). Ensaios de Western Blot também foram 
realizados para avaliar a influência da co-expressão da PPA e Gαo em 
proteínas do citoesqueleto. 
Os nossos resultados mostram que a Gαo e a PPA parecem colocalizar 
principalmente no aparelho de Golgi e nos prolongamentos celulares. Ambas 
as proteínas parecem cooperar entre si e induzir alterações neuritogénicas, 
com a Gαo a levar principalmente a uma formação inicial dos prolongamentos e 
a PPA a atuar na extensão dos mesmos, num modo dependente da 
fosforilação da S655. Além disso, observou-se que a PPA diminui a ativação 
da STAT3 induzida pela Gαo, devido provavelmente a um efeito de retro-
inibição. Estes resultados provam que estas proteínas interagem 
funcionalmente e o seu potencial valor em aplicações neuritogénicas 
terapêuticas será estudado em maior detalhe. 
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abstract 
 
The Gαo protein is an alpha subunit of the heterotrimeric G proteins, a protein 
family vastly involved in signal transduction from membranar receptors. Gαo is 
enriched in the plasma membrane of neurons, including neurons growth cone, 
together with the Alzheimerʼs amyloid precursor protein (APP), a 
transmembranar protein with a central role in Alzheimer's Disease. A few 
similar functions have been attributed to both proteins, such as roles in cell 
differentiation and migration. APP binding to Gαo has been reported, which 
could indicate that APP modulates its functions by binding and activating Gαo. 
Further, one of the pathways by which Gαo leads to neurite outgrowth is by 
activation of the signal transducer and activator of transcription 3 (STAT3). Gαo 
binds to the APP C-terminal domain, namely at amino acids His657-Lys676, 
which belong to a hydrophobic pocket localized immediately downstream the 
APP 653YTSI656 basolateral sorting motif. Therefore, APP binding to Gαo may be 
potentially mediated by APP phosphorylation at the Serine 655 residue (S655), 
and thus APP phosphorylation could influence Gαo activation and STAT3 
signalling.  
In this work we have studied the effects of APP phosphorylation and Gαo  
activation in Gαo/APP functional interactions. This was analysed by 
cotransfecting human non-differentiated neuroblastoma (SH-SY5Y) cells  with 
either Wt or phosphomutants of APP-GFP (APP with either a constitutively 
phosphorylated or dephosphorylated S655) and Gαo or a constitutively active 
Gαo cDNA.  Cells were subjected to immnofluorescence assays, and several 
parameters analysed, such as the subcellular colocalization of Gαo and APP, 
the number of cellular projections and their length, and nuclear STAT3 
intensity. Every quantitative analysis done upon microphotographs was 
performed using the Fiji (ImageJ) software. Western blot assays were also 
performed to evaluate the influence of APP and Gαo co-expression in 
cytoskeleton-related proteins. 
Our results show that Gαo and APP appear to colocalize mainly in the Golgi 
apparatus and in cellular projections. Both proteins appear to cooperate with 
each other and induce neuritogenic changes, with Gαo mainly driving an initial 
formation of cellular projections and APP influencing their elongation, in an APP 
S655 phosphorylation-dependent manner. Moreover, APP was observed to 
decrease Gαo-induced STAT3 activation, probably by a  retro-inhibition effect 
upon earlier STAT3 activation. These results prove that these proteins 
functionally interact, and their potential value in neuritogenic therapeutic 
applications will be further studied. 
 
 
 
	   	   SACS/UA	  2012	  
Roberto	  Alexandre	  dos	  Santos	  Dias	   	   1	  
Index	  
Abbreviations .................................................................................................................... 3 
1. Introduction .................................................................................................................. 5 
1.1. G protein-coupled receptors ................................................................................... 5 
1.2. Guanine Nucleotide-Binding Proteins ................................................................... 6 
1.2.1 G proteins families ........................................................................................... 7 
1.2.2. Modulators of G protein activity ..................................................................... 9 
1.3. The Other Guanine Nucleotide-Binding Protein ................................................. 10 
1.3.1. Go genetics ..................................................................................................... 11 
1.3.2. Modulators of Go activity .............................................................................. 11 
1.3.3. Go expression pattern .................................................................................... 12 
1.3.4. Go functions ................................................................................................... 13 
1.4. The Alzheimer's Amyloid Precursor Protein ....................................................... 15 
1.4.1. APP processing ............................................................................................. 17 
1.4.2. APP trafficking .............................................................................................. 18 
1.4.3. APP phosphorylation ..................................................................................... 19 
1.5. Go binding to APP ................................................................................................ 20 
1.5.1. Go:APP and Alzheimer's Disease .................................................................. 21 
1.5.2. APP and Gαo in neuritogenesis ...................................................................... 21 
2. Aims ............................................................................................................................ 23 
3. Methods ...................................................................................................................... 25 
3.1. Wild type (Wt) and S655 Phosphomutants APP-GFP cDNAs ............................ 25 
3.2. Wt and Constitutively Active Gαo cDNAs ........................................................... 25 
3.3. Gαo and constitutively active Gαo cDNAs amplification and purification ........... 25 
3.3.1. Bacterial transformation ................................................................................ 25 
3.3.2. MegaPrep DNA Purification ......................................................................... 26 
3.3.3. Ethanol precipitation of plasmid DNA .......................................................... 26 
3.4.  Culture and maintenance of the SH-SY5Y cell line ........................................... 27 
3.5. Transfection of the SH-SY5Y cell line with APP-GFP and Gαo cDNAs ............ 27 
3.5.1. JetPRIME® transfection ................................................................................ 27 
3.5.2 TurboFectTM transfection ............................................................................... 28 
3.5.3 CombiMagTM transfection .............................................................................. 28 
3.6.  Cell collection and quantification of protein content .......................................... 29 
SACS/UA	  2012	  
2	   	   Roberto	  Alexandre	  dos	  Santos	  Dias	  
3.7. Antibodies ............................................................................................................ 29 
3.8. Western Blot assay ............................................................................................... 31 
3.9. Ponceau Red staining of protein bands ................................................................ 32 
3.10. Immunocytochemistry assay .............................................................................. 32 
3.11. Image analysis .................................................................................................... 33 
3.12. Data analysis ...................................................................................................... 33 
4. Results ........................................................................................................................ 35 
4.1. Optimization of the transfection method and antibodies dilutions ...................... 35 
4.2. Effects of APP S655 phosphorylation and Gαo activation in APP/Gαo subcellular 
colocalization .............................................................................................................. 36 
4.3. Gαo/APP-induced alterations in cellular morphology .......................................... 42 
4.4. Analysis of cytoskeleton-related protein profiles ................................................ 44 
4.5. Effects of APP in Gαo-induced STAT3 activation ............................................... 46 
4.5.1. Nuclear STAT3 changes in response to Gαo overexpression ........................ 46 
4.5.2. APP phosphorylation influences Gαo-induced STAT3 activation ................. 49 
5. Discussion ................................................................................................................... 55 
6. Conclusion .................................................................................................................. 63 
References ...................................................................................................................... 65 
Appendix ........................................................................................................................ 75 
 
 
 
 
 
 
 
 
	   	   SACS/UA	  2012	  
Roberto	  Alexandre	  dos	  Santos	  Dias	   	   3	  
Abbreviations  
AD 
 
Alzheimer’s disease  
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1. Introduction 
1.1. G protein-coupled receptors 
 The ability of cells to interact with each other or with the environment 
surrounding them is essential for organisms’ survival. From simple bacteria to advanced 
multicellular eukaryotes, cells are gifted with mechanisms that enable them to receive a 
signal from the extracellular environment and transform it in an intracellular response, a 
process called signal transduction (Table 1) (Lodish, 2003; Lehninger et al., 2005). 
 
 
Table 1 - Some of the signals to which cells respond. Adapted from Lehninger et al., 2005 
Antigens Light 
Cell surface glycoproteins/oligosaccharides Mechanical touch  
Extracellular matrix components Neurotransmitters 
Growth factors Nutrients 
Hormones Odorants 
Development signals Pheromones 
Tastants  
 
  
 One of the main mechanisms by which cells perform signal transduction is based 
on the activation of guanine nucleotide-binding proteins (G proteins) by G protein-
coupled receptors (GPCRs). The human genome has over 800 genes that encode 
GPCRs, making them the largest family of transmembrane receptors. Several hormones, 
neurotransmitters and sensory stimuli act upon cells through GPCRs (Offermanns, 
2003; Milligan and Kostenis, 2006). Each GPCR contains seven transmembrane helical 
regions, an extracellular N-terminus and an intracellular C-terminus (Fig. 1). Upon the 
binding of a ligand to a GPCR, the receptor suffers a conformational change that 
enables it to interact and activate a heterotrimeric G protein (Kroeze et al., 2003; 
Lodish, 2003). 
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1.2. Guanine Nucleotide-Binding Proteins  
 Heterotrimeric G proteins consist of three subunits, α, β and γ. The Gα subunit 
has a GTPase activity and alternates between an active state when bound to GTP and an 
inactive state when bound to GDP. The β and γ subunits form a single complex 
normally designated Gβγ subunit (Lodish, 2003; Offermanns, 2003). While initially it 
was thought that only Gα interacted with the effector proteins, it is now known that both 
the Gα and Gβγ are responsible for transducing the signal to their respective effector 
proteins (Offermanns, 2003; Milligan and Kostenis, 2006). 
 In an inactivated state, the Gα subunit is bound to a GDP molecule and forms a 
complex with the Gβγ subunit. As aforementioned, after the binding of a ligand to a 
GPCR, a conformational change occurs that allows it to bind to the heterotrimeric G 
protein, which results in the release of GDP and binding of GTP to Gα. This reaction 
results in the dissociation of Gα from Gβγ, allowing both subunits to interact and 
modulate the activity of several effector proteins. G proteins remain active only for 
short periods of time due to the intrinsic GTPase activity of Gα, which hydrolyzes GTP 
to GDP, leading to the reassociation of Gα with Gβγ, returning the G protein to its 
inactive form (Fig. 2) (Kroeze et al., 2003; Offermanns, 2003; Milligan and Kostenis, 
2006).  
Figure 1 - Representation of a G protein-coupled receptor. Reproduced 
from Lodish, 2003. 
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 1.2.1 G proteins families 
 Several mammalian genes that codify Gα subunits have already been identified, 
16 of which are present in humans (Gomperts et al., 2009). Since the main properties of 
G proteins are related to their α subunits, these have been used to divide G proteins in 
four subfamilies according to their functional and structural homologies: Gi/o, Gs, Gq/11 
and G12/13 (Table 2) (Offermanns, 2003; Jiang and Bajpayee, 2009). 
 The main members of the Gi/o family are Gi proteins. These type of G proteins 
have an inhibitory effect on adenylyl cyclase activity (hence G"i"), preventing it to 
catalyze the formation of the second messenger cAMP and thus affecting processes 
within the cell (Offermanns, 2003; Lehninger et al., 2005; Jiang and Bajpayee, 2009). 
Gt (transducin) and Ggust (gustducin) proteins are also members of the Gi/o family and are 
involved mainly in visual and taste functions, respectively (Offermanns, 2003; Milligan 
and Kostenis, 2006). The Go protein, which also belongs to this class, will be discussed 
further ahead.  
Figure 2 - The G protein activation/deactivation cycle. Reproduced from Milligan and Kostenis, 2006. 
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 The Gs family members have the primary function of activate adenylyl cyclases 
("stimulatory"), leading to the production of cAMP. Gs and Golf are the main members, 
with Gs being ubiquitously expressed and Golf (olfactory) being mainly expressed in 
olfactory sensory neurons and in the central nervous system (Simonds, 1999; 
Offermanns, 2003). 
 The Gq/11 proteins are widely expressed in humans and act as mediators in the 
regulation of phospholipase C β-isoforms. These proteins, unlike Gi/o, are insensitive to 
the action of pertussis toxin (PTX), a protein that catalyzes ADP-ribosylation of the Gαi 
and Gαo subunits, rendering them incapable of performing their normal functions 
(Offermanns, 2003; Milligan and Kostenis, 2006; Locht et al., 2011). 
 The G12 and G13 are also widely expressed in human cells, although the 
receptors by which they are activated and the effectors with which they interact are not 
yet fully understood. Studies with constitutively active forms of both G proteins have 
led to the implication of these proteins in cell proliferation, morphology and cadherin-
mediated signalling (Riobo and Manning, 2005; Milligan and Kostenis, 2006). 
 There are also different β and γ subunits (5β and 12γ have already been 
identified). Even though the βγ subunits have important functions in transducing 
signals, the different combinations between both subunits do not appear to affect their 
action, nor do the combination between different α and βγ subunits, although this has 
not been tested well enough. Since there are a few significant differences between some 
of the subunits, there is reason to believe that they may have different functions. Also, 
not all possible combinations are present in every cells (Offermanns, 2003; Milligan and 
Kostenis, 2006).  
  
Table 2 - Gα subunits genes, expression patterns and known effectors. Adapted from Offermanns, 
2003; Milligan and Kostenis, 2006. 
Name Gene  Expression Effector/Action 
Gi/o Family    
    Gi1   Gnai1 Widely distributed Adenylyl cyclases and Ca2+ channels 
decreased function; K+ channels and 
GTPase of tubulin increased function 
    Gi2 Gnai2 Ubiquitous 
    Gi3 Gnai3 Widely distributed 
    Go Gnao 
Neuronal, 
neuroendocrine 
Ca2+ channels decreased function; K+ 
channels increased function, Adenylyl 
cyclases inhibition (exclusive of Gαo-2 
isoform) 
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    Gz Gnaz Neuronal, platelets 
Ca2+ channels decreased function; K+ 
channels increased function 
    Ggust Gnag Taste cells, brush cells Not known 
    Gt1 Gnat1 
Retinal rods, taste 
cells cGMP-PDE increased function 
    Gt2 Gnat2 Retinal cones 
Gs Family    
    Gs Gnas Ubiquitous 
Adenylyl cyclases, Src tyrosine 
kinases, GTPase of tubulin increased; 
    Golf Gnal 
Olfactory neurons, 
brain Adenylyl cyclases increased 
Gq/11 Family    
    Gq Gnaq Ubiquitous 
Phospholipase Cβ isoforms and K+ 
channels increased function 
    G11 Gna11 Almost ubiquitous p63-RhoGEF increased function 
    G14 Gna14 Kidney, lung, spleen 
Not known 
    G16 Gna15 Hematopoietic cells  
G12/13 Family    
    G12 Gna12 Ubiquitous Phospholipase D and Cε increased 
function; E-cadherin-mediated cell 
adhesion increased      G13 Gna13 Ubiquitous 
 
 
 1.2.2. Modulators of G protein activity  
 The activation/deactivation cycle of G proteins can be regulated by several 
proteins that can be divided into two groups: Regulators of G-protein Signalling (RGS) 
and guanine nucleotide exchange factors (GEFs) (Fig. 3).  
  RGS have over 30 intracellular proteins already discovered. These can modulate 
G protein activity mainly by increasing their rate of hydrolysis of GTP by the Gα 
subunit and thus inactivating G proteins more quickly. Because of this function, RGS 
proteins are also called GTPase-activating proteins (GAPs), however this designation is 
used more often to describe the proteins that have this same function but interact with 
small monomeric G proteins, like Ras (Gomperts et al., 2009). Besides GAP activity, 
RGS proteins can physically block the interaction between Gα and effector proteins, and 
increase the affinity of Gα to Gβγ, which leads to rapid reassembling of the heterotrimeric 
SACS/UA	  2012	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form of G proteins after GTP hydrolysis, thus preventing Gβγ subunits of interacting 
with their effector proteins (De Vries et al., 2000; Roman and Traynor, 2011). 
 GEFs are able to activate G proteins by increasing the rate of exchange of GDP 
by GTP. GPCRs are the most well known proteins that act as GEFs of heterotrimeric G 
proteins (De Vries et al., 2000; Jiang and Bajpayee, 2009). 
 
 
 
 
 
 
 
 
 
 
 
1.3. The Other Guanine Nucleotide-Binding Protein 
 The Go protein is the most expressed G protein in the central nervous system, 
where it accounts for about 1% of total membrane protein. It was accidentally 
discovered in 1984 when researchers were trying to isolate Gi protein from bovine brain 
and detected an extra Gα subunit with a molecular weight of 39 kDa, naming it the 
"other" G protein, to differentiate from Gi and Gs (Sternweis and Robishaw, 1984; Jiang 
and Bajpayee, 2009). Since then, it has been intensively studied and several GPCRs, 
among other proteins, had already been discovered to interact with Go; however, its 
main functions are not yet fully understood. Being highly expressed in brain tissue, Go 
as been implicated in neuronal development, migration, and such diseases as 
Alzheimer's and Parkinson's (Jiang et al., 1998; Jiang and Bajpayee, 2009).	    
Figure 3 - Modulation of G proteins action by Regulators of G-protein signalling (RGS) and 
guanine nucleotide exchange factors (GEFs). Reproduced from(Siderovski and Willard, 2005) 
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 1.3.1. Go genetics  
 Go protein has already been identified in several species, such as rat, mouse, 
bovine, Drosophila and human, among others. Comparison between DNA sequences of 
the different Go genes showed that this protein is highly conserved across species, 
which suggests that Go signalling is extremely important for organisms to receive, 
integrate and execute extracellular signals (Murtagh et al., 1991; Jiang and Bajpayee, 
2009). 
 The human Gαo gene comprises over 100 kb and contains 11 exons, being 
localized in chromosome 16 (Tsukamoto et al., 1991). Analysis of bovine and mouse 
brains have led to the discovery of two isoforms of Gαo, Gαo-1 and Gαo-2 (also called Gαo-
A and Gαo-B), which were later found in human cells. Both isoforms are identical in the 
first two thirds of the amino acid sequence, differing only in 20 amino acids in the latter 
third of the protein. Study of the human gene found that the exon 8 and 9 are duplicated, 
and that Gαo-1 contains exon 7-A and 8-A while Gαo-2 contains exon 7-B and 8-B. This 
indicates that both isoforms are a product of alternative splicing, and since exon 7 and 8 
are thought to be necessary to receptor and effector binding, these isoforms may have 
different functions in the human brain (Lang, 1989; Hsu et al., 1990; Tsukamoto et al., 
1991; Jiang and Bajpayee, 2009). 
 
 
 1.3.2. Modulators of Go activity 
 Being a member of the Gi/o family, Go suffers ADP-ribosylation by PTX in its 
carboxyl terminal cysteine residue of the α subunit, inactivating it (Jiang and Bajpayee, 
2009; Locht et al., 2011). A few RGS proteins have been identified that accelerate the 
process of Go inactivation, being one of those proteins the Gα-interacting protein 
(GAIP). This protein has been found to specifically interact with Go, only losing that 
specificity when its N-terminal was deleted (Diverse-Pierluissi et al., 1999; Jiang and 
Bajpayee, 2009). 
 Several GPCRs that are able to exert their action trough Go proteins have already 
been identified, including opioid, α2-adrenergic, M2 muscarinic and somatostatin 
receptors (Jiang et al., 1998). All of these act as GEFs, causing Go to dissociate from 
GDP and bind GTP. Beside GPCRs, other molecules have been identified that activate 
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Go, such as the growth cone-associated protein with a molecular weight of 43 kDa 
(GAP43), the activator of G protein signalling (AGS), the Presenilin I enzyme and the 
Alzheimer's Amyloid Precursor Protein (APP) (Jiang and Bajpayee, 2009). GAP43, a 
protein expressed in developing neurons, is thought to act upon Go in a manner similar 
to GPCRs. However its action is not affected by the presence of PTX or the βγ subunit, 
which leads to the believe that is mechanism of action is somehow different of other 
GEFs (Strittmatter et al., 1991; Jiang and Bajpayee, 2009). AGS studies in vitro showed 
that this protein enhanced GTPγS binding to both Gi and Go (Cismowski et al., 2000). A 
physical interaction between Presenilin I and Go has been described, which led to the 
possibility of this protein performing its functions through Go. Besides that, the 
interaction of the two proteins could also be implicated in Alzheimer's disease (Smine et 
al., 1998; Jiang and Bajpayee, 2009). The interaction between Go and APP will be 
discussed in more detail further ahead.  
 Other factors have also been identified that interact and possibly modulate Go 
activity. However, their exact mechanism and effect are not fully comprehended. Such 
is the case of GoLoco motif, a 19 amino acid sequence originally found in the RGS12 
protein that binds to Gαo, though is not known whether it acts as a GEF or rather 
decreases Go activity by stabilizing it in the GDP-bound form (Siderovski et al., 1999; 
Jiang and Bajpayee, 2009). 
 
 
 1.3.3. Go expression pattern  
 Go protein is expressed mainly in the central nervous system (CNS), however, its 
distribution along the brain does not appear to be equal. Immunohistochemical studies 
in rat brains showed that Go is highly present in the cerebral cortex, cerebellum, 
hypothalamus, hippocampus and substantia nigra, being located mainly in the 
cytoplasmatic face of the plasma membrane, including cell-to-cell contacts (Worley et 
al., 1986; Gabrion et al., 1989). Besides CNS, Go has also been located in the heart 
tissue, pituitary gland and pancreatic isles (Wolf et al., 1998; Jiang and Bajpayee, 
2009). 
 Go expression was also studied in different stages of neuronal differentiation. In 
undifferentiated neuroblastoma x glioma hybrid cells, Go levels were very low but after 
these cells suffered differentiation, Go levels significantly increased. Besides that, only 
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Go2 isoform is expressed in undifferentiated cells, whereas both Go1 and Go2 were 
expressed in differentiated cells, a factor that contributes to the increase in Go protein 
levels (Mullaney and Milligan, 1989; Brabet et al., 1991).  
 
 
 1.3.4. Go functions 
 The Go protein seems to have several functions mediated through a large number 
of effector molecules. Most of those functions involve the modulation of ion channels, 
kinases activity and vesicular transporters (Jiang and Bajpayee, 2009). 
  
Calcium channels: Several neurotransmitters and hormones that inhibit voltage-
gated Ca2+, such as noradrenaline and somatostatine, have been known to act through 
GPCRs. Initial studies using PTX on neurons led to the discover that the inhibitory 
effect of the neurotransmitter over the calcium channels was lost when the toxin was 
present, which suggested that PTX-sensitive G proteins, such as Gi and Go, were 
involved (Holz et al., 1986; Hille, 1994; Jiang and Bajpayee, 2009). Further studies 
using antibodies specific for the Gαo subunit showed that the inhibitory effect of 
noradrenaline was diminished when the antibodies were applied (Caulfield et al., 1994).  
 
 Potassium channels: Like in the calcium channels, there are neurotransmitters 
that interact with K+ channels through PTX-sensitive G proteins. Experiments using 
membranes of hippocampal pyramidal cells allowed to identify four K+ channels that 
were activated by purified Go proteins and a recombinant Gαo subunit (VanDongen et 
al., 1988; Jiang and Bajpayee, 2009). 
 The activation of K+ channels by Go was also studied in the heart muscle and 
peripheral neurons. However the results showed that it was the βγ subunit of the 
heterotrimeric complex rather than the α subunit that interacted and activated the K+ 
channels (Huang et al., 1997; Lei et al., 2000). 
 Besides potassium and calcium channels, Go also appears to be involved in the 
regulation of sodium channels, however the receptors involved in this pathway have not 
yet been identified (Jiang and Bajpayee, 2009).  
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 MAPK pathway: several studies indicate that Go is involved in the activation of 
the mitogen-activated protein kinase (MAPK) pathway (Jiang and Bajpayee, 2009). For 
example, one of those studies demonstrated that a constitutively active Gαo was able to 
activate B-Raf in a Protein Kinase C (PKC)-dependent manner and consequently 
stimulate the MAPK pathway (Antonelli et al., 2000). 
  
 STAT3 pathway: The signal 
transducer and activator of transcription 3 
(STAT3) is a known proto-oncogenic 
protein that is involved in the development 
of several cell lines, from hematopoietic 
cells to neurons. It was recently found that 
STAT3 can be activated by receptors 
coupled to Go (He et al., 2005; Hankey, 
2009). One of those receptors is the 
cannabinoid receptor (CBR1), which, when 
activated, leads to the stimulation of the 
STAT3 pathway. This mechanism appears 
to involve the direct interaction between Go 
and regulators of small monomeric G 
proteins, such as Rap1 and its GAP protein, 
that are present in the STAT3 pathway. This 
results in the activation of Scr tyrosine 
kinase, culminating in the phosphorylation 
of STAT3 (Fig. 4). This Go-signalling was 
observed in Neuro-2A cells, which led to 
neurite outgrowth (He et al., 2005).  
  
Vesicular transporters: Go proteins are present in both secretory granules and 
small synaptic vesicles in bovine and rat brain. The exact mechanism in which Go is 
involved in these structures is still not well known, however a few possible functions 
have been proposed. One of those is the control of the uptake of neurotransmitters, since 
activation of Go2 inhibits the uptake of noradrenaline in PC12 cells (Ahnert-Hilger et al., 
 
Figure 4 - STAT3 Pathway leading to neurite 
outgrowth. Reproduced from(He et al., 2005) 
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1994; Ahnert-Hilger et al., 1998). It was also demonstrated that Go interacts with small 
G proteins (Rho) in a mechanism necessary for the reorganization of neurons 
cytoskeleton in the exocytosis process (Jiang and Bajpayee, 2009). 
  
 Go protein seems to have significant importance in the brain due to its abundance 
in this tissue. Studies in mice lacking Go revealed that the absence of the protein led to 
severe motor control deterioration, hyperactive behaviour and hyperalgesia (Jiang et al., 
1998).  The molecular role of Go in the brain has been studied and its interaction, 
directly or indirectly, with other brain proteins have led to the discovery of a few 
specific roles. One of those signalling pathways has already been described above, the 
STAT3. Another one is the Growth Associated Protein 43 (GAP-43), a protein highly 
expressed in the growth cones of developing and regenerating neurons, which indicates 
that it may be involved in neurite growth (Strittmatter et al., 1991; Strittmatter et al., 
1994). Like stated above, GAP-43 is a known GEF for Go protein, leading to the believe 
that GAP-43 is able to modulate neurite growth and motility through Go activation. 
Strittmatter et al have already produced some results that indicate just that. In their 
studies, GAP-43 was shown to increase neurite outgrowth by stimulating Go in 
neuroblastoma cells (Strittmatter et al., 1994). Another study using constitutively 
activated Gαo (a mutated Gαo lacking its GTPase activity) showed that increase in 
neurite outgrowth could be caused by inhibition of PKC and modulation of intracellular 
calcium release (Xie et al., 1995). 
 Another important role of Go in the brain appears to be its involvement in 
Alzheimer's Disease, an hypothesis that arrived with the discovery that Go interacts with 
the Alzheimer’s Amyloid Precursor Protein (Nishimoto et al., 1993). 
	  
	  
1.4. The Alzheimer's Amyloid Precursor Protein 
 Alzheimer's Amyloid Precursor Protein (APP) is a transmembrane protein 
mainly present in the Golgi and plasma membrane of neuronal cells. Its specific 
functions are still not very clear, but it is thought to be involved in cell adhesion 
signalling, neurite outgrowth and synaptic contact, being also the precursor protein of β-
amyloid (Aβ) (Small, 1998; Thinakaran and Koo, 2008). The Aβ peptide is the main 
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component of amyloid plaques (also called senile plaques), one of the main features of 
Alzheimer's Disease (AD), and it has been associated to most of the pathological 
changes that occur during the progress of AD, such as induction of inflammatory 
reactions, neuronal dysfunction, synapse loss and cell death (Hardy and Higgins, 1992; 
Sommer, 2002; Henriques et al., 2010). Its production depends on the processing of 
APP, a process that will be explained further ahead.  
 APP arises from the expression of a gene located in the chromosome 21. There 
are several isoforms resulting from alternative splicing, with APP695 being the most 
common in the brain (the number represents the amino acids content of the protein) 
(Fig. 5). APP has only one transmembranar domain, with most of the protein being 
located in the extracellular space and just a small C-terminal domain being located in 
the intracellular space (Small, 1998; Ling et al., 2003). After its expression, APP suffers 
several post-translational modifications that are essential for its function, such as 
glycosylation and phosphorylation. 
 
Figure 5 - Different isoforms of APP. Reproduced from Edgar F. da Cruz e Silva and Odete A. B. da 
Cruz e Silva, 2003  
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 1.4.1. APP processing 
 APP can be cleaved by several secretases, giving rise to some peptides with 
important physiological and pathological function. Those secretases are mainly divided 
in α, β and γ secretases and depending on which of these cut APP, Aβ may or may not 
be generated (Figure 6). γ-secretase cuts the APP transmembrane domain on several 
sites. Its action gives rise to AICD (APP intracellular domain), a peptide that has been 
implied in a few signalling pathways. AICD can bind to Fe65, which results in the 
formation of a complex responsible for the activation of the transcription of several 
genes, including p53, GSK-3β, Kai1, among others. However, the precise mechanism 
by which AICD binding to Fe65 leads to gene transcription is not well known (Ling et 
al., 2003; Thinakaran and Koo, 2008; Chow et al., 2010).  
 The action of the other two secretases defines the processing pathway of APP. In 
the non-amyloidogenic pathway (Fig. 6 - left), α-secretase cuts APP in the Aβ region, 
generating secreted APPα (sAPPα) and a C-terminal fragment (α-CTF), the latter being 
then cleaved by the γ-secretase, originating the p3 fragment and AICD. In this pathway, 
no Aβ is generated (hence non- amyloidogenic), which is why this process is normally 
dubbed neuroprotective. Further, the formation of sAPPα also contributes to the 
neuroprotective function of the non-amyloidogenic pathway. The precise mechanisms 
  Figure 6 - Non-amyloidogenic (left) and amyloidogenic pathway (right). Reproduced from 
(Thinakaran and Koo, 2008) 
SACS/UA	  2012	  
18	   	   Roberto	  Alexandre	  dos	  Santos	  Dias	  
in which sAPPα is involved are not fully understood, but studies indicate that it 
promotes neurite outgrowth, synaptogenesis and cell adhesion, and protects neurons 
against oxygen deprivation and excitotoxicity (Ling et al., 2003; Gakhar-Koppole et al., 
2008; Chow et al., 2010). No function as yet been assigned to the non pathogenic p3 
fragment (Ling et al., 2003). 
 On the other hand, the cut of APP by the β-secretase is termed amyloidogenic 
pathway (Fig. 6 - right). The β-secretase cuts APP in its β-cleavage site, generating 
sAPPβ and C99 (or β-CTF). The C99 is then cleaved by γ-secretase, giving rise to Aβ 
(hence amyloidogenic) and AICD. The main β-secretase involved in this pathway is 
BACE1 (β-site APP-cleaving enzyme 1). The sAPPβ has still not a clear function (Ling 
et al., 2003; Cole and Vassar, 2008; Chow et al., 2010).  
  
 
 1.4.2. APP trafficking  
 The first steps in APP post-translational modification are its N- and O-
glycosylation, followed by its phosphorylation and tyrosine sulfation. These occur 
during its transport from the endoplasmic reticulum to the plasma membrane (Figure 7, 
step 1). However, only a small portion of the expressed APP is localized to the plasma 
membrane. Most of it remains in the Golgi apparatus or in the Trans-Golgi network 
(TGN) (Thinakaran and Koo, 2008; Zheng and Koo, 2011).  
 In the plasma membrane, APP can suffer non-amyloidogenic processing, due to 
the presence of the α-secretase in the membrane. On the other hand, shortly after its 
integration in the membrane, APP is internalized by endocitosis (Figure 7, step 2) and 
can either be degraded in lysosomes or recycled back to the membrane (Fig. 7, step 3). 
During this transport, APP comes in contact with BACE1 in several compartments, 
such as the endosome and the TGN. This promotes the amyloidogenic processing of 
APP and consequently Aβ generation. It has been shown that several proteins, like 
Fe65, interact with the APP C-terminal and modulate its intracellular trafficking, 
interfering with the production of Aβ (Small and Gandy, 2006; Thinakaran and Koo, 
2008).  
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Figure 7 - APP trafficking. Reproduced from(Thinakaran and Koo, 2008)    
 
 1.4.3. APP phosphorylation 
 The processing, trafficking and function of APP is regulated in many ways, with 
phosphorylation appearing to have an important part in all of these processes. A few 
phosphorylation sites have been identified in both the intracellular and extracellular 
domain of APP. The serines 198 and 206 are the amino acids phosphorylated in the 
APP ectodomain, but no relevant function have been so far attributed to these 
phosphorylations (Walter et al., 1997; da Cruz e Silva and da Cruz e Silva, 2003).  
 On the other hand, some of the phosphorylation sites discovered in the 
intracellular domain of APP have a significant impact in its life. These include the 
Thr654, Ser655, Thr668, Tyr682 and Tyr687. The Thr668 is one of the best studied 
phosphorylatable amino acids of APP, being phosphorylated by GSK-3β, Cdk5 and 
JNK, although its role is still controversial. Thr668 phosphorylation has been linked to 
both increases and decreases in Aβ formation and in the regulation of the binding of 
AICD to Fe65 followed by translocation of the complex to the nucleus, or not having 
any effect in this process (Suzuki and Nakaya, 2008; Schettini et al., 2010).  
 Phosphorylation of Serine 655 (S655), present in the YTSI sorting sequence, 
potentially by protein kinase C, has been described as an important event in APP 
processing, trafficking and its interaction with other proteins. A study using APP 
phosphomutants mimicking a constitutively phosphorylated and a constitutively 
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dephosphorylated S655 (S655E and S655A, respectively) showed that S655 
phosphorylation increased APP trafficking through the Golgi to the plasma membrane, 
and an increase in sAPPα production. The two events are most likely related since the 
continuous trafficking of APP renders it more available to α-secretase cleavage (Vieira 
et al., 2009). Another study showed that S655 phosphorylation leads to an increase in 
APP recycling through a retromer mediated process. It also decreases APP targeting to 
lysosomes, thus expanding its half-life (Vieira et al., 2010).   
 Interestingly, the binding of APP to Gαo (discussed in more detail further ahead) 
occurs immediately downstream of the sorting motif 653YTSI656, which can indicate that 
APP S655 phosphorylation may influence the interaction between both proteins.  
 
 
1.5. Go binding to APP 
 APP was found to selectively bind to Gαo, but not Giα, through APP His657-Lys676 
domain, and described to activate Gαo (Nishimoto et al., 1993). Further studies 
involving phospholipid vesicles containing both APP695 and Go identified APP as a 
GPCR-like protein, with a possible natural ligand not yet identified but who's action 
was mimicked by 22C11, an antibody directed against the extracellular domain of APP. 
When the antibody bound to APP, Go activation was greatly enhanced due to an 
increase in the GDP/GTP exchange rate. The ability of APP695 to activate Gi in the 
presence of 22C11 was also tested, with negative results, indicating that APP binds 
specifically to Go protein (Okamoto et al., 1995). 
 A more recent study shed a new light in the mechanism by which APP activates 
Go. This study also evaluated the action of the 22C11 in the interaction of APP to Go, 
however the results showed a decrease in the GTPase activity of Go, a phenomenon not 
detected in the earlier study. The authors attributed this difference of results to the fact 
that the study conducted by Okamoto et al, was done using phospholipid vesicles, which 
probably lack a few cofactors needed to the decrease in the Go GTPase activity. Since 
this decrease would make Go active for longer periods of time, this could be an 
alternative mechanism by which APP increases the activity of Go proteins. However, 
this is not yet certain, with further research being required (Brouillet et al., 1999).  
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 1.5.1. Go:APP and Alzheimer's Disease 
 Mutations in the APP gene have already been identified in cases of genetic-
linked Familial Alzheimer's Disease (FAD). One class of specific mutations is the 
V642, where the valine at the 642 position is mutated into isoleucine (V642I), 
phenylalanine (V642F) or glycine (V642G) (Hardy, 1992; Karlinsky et al., 1992). All 
these mutations were shown to cause apoptosis in COS-NK1 cells in a Go-mediated 
mechanism, since knockout of Go, but not Gi, led to the suppression of apoptosis (Fig. 
8). Go involvement was also tested by transfecting COS cells with V642-APPs mutants 
lacking the His657-Lys676 sequence. In these cells, apoptosis was also greatly diminished 
in comparison with V642-APPs mutants, giving stronger evidences of the mediating 
function of Go in APP-induced apoptosis (Yamatsuji et al., 1996). To clarify which of 
the Go subunits was responsible for the activation of the apoptosis cascade, a series of 
tests were made in NK1 cells involving constitutively activated Gαo (Q205L) and 
βARK1 C-terminus, a binding site to Gβγ subunits that inhibits its functions. The results 
showed that constitutively activated Gαo induced little apoptosis while βARK1 C-
terminus inhibited NK1 apoptosis, leading to the conclusion that Gβγ subunit, and not 
Gα, was responsible for triggering apoptosis (Giambarella et al., 1997).   
 
  
 
 1.5.2. APP and Gαo in neuritogenesis 
 Since some of the functions of APP have also been attributed to the Go protein, it 
was hypothesized that APP could mediate its functions through Go, acting most likely as 
a Gαo GEF (Nishimoto et al., 1993; Okamoto et al., 1995; Okamoto et al., 1996). 
 One of those functions is neuritogenesis. As stated above, Gαo induction of 
neurite outgrowth has already been described via STAT3 pathway. A different pathway 
Figure 8 - Mediation of V642-APP-induced apoptosis by Go protein. Adapted from Yamatsuji et 
al, 1996 
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by which Gαo could lead to neurite growth is by activation of the G Protein-Regulated 
Inducer of Neurite Outgrowth 1 (GRIN1) (Nakata and Kozasa, 2005), however in this 
work we will focus on the STAT3 pathway.  
 APP role on neuritogenesis has also been described. Initial studies showed that 
APP expression increased neurite length and branching in PC12 cells, possibly by 
mediating the Nerve Growth Factor action (Milward et al., 1992). Another study 
analyzed the effect of down-expression of APP on neuronal primary cultures. The 
results indicated that the blockage of APP expression leads to a decrease in axon and 
dendritic growth (Allinquant et al., 1995).  
 More recent studies indicate that while APP clearly influences neuritogenesis, it 
may have an inhibitory effect rather than stimulatory. Also, sAPPα seems to be 
fundamental to regulate APP function. In one of those studies, loss of APP expression 
in primary neuronal culture culminated in increased neurite elongation, with this same 
result occurring when sAPPα was applied to the cells expressing APP. Both these 
effects were blocked with the use of antibodies directed against Integrin β1. The 
hypothesis defended was that full-length membranar APP is able to interact with 
Integrin β1 leading to the inhibition of neurite outgrowth, while sAPPα blocks this 
interaction and thus allows neurite elongation (Young-Pearse et al., 2008). 
 Previous work developed in our lab was dedicated to understanding the role of 
APP in neuronal differentiation (Rocha, 2011). The study was conducted in SH-SY5Y 
cells and showed that while long-term overexpression of APP could have a negative 
effect on neuritogenesis, short-term expression (24h) leads to an increase in neurite 
outgrowth. Also, with the use of phosphomutants APP-GFP cDNAs, the positive 
neuritogenic action of APP was found to be enhanced by APP S655 phosphorylation. 
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2. Aims 
This work focused on characterizing the interaction between the Alzheimer's 
Amyloid Precursor Protein and Gαo protein, with its main aims being: 
• To evaluate the effects of APP S655 phosphorylation and Gαo constitutive 
activation in APP-Gαo colocalization in SH-SY5Y cells. 
• To study the effect of APP-Gαo co-expression in the induction of cellular 
morphological changes, and how APP phosphorylation and Gαo activation 
regulate that effect(s). 
• To analyse the impact of Gαo and APP co-expression in cytoskeleton-related 
proteins.  
• To evaluate the effect of APP phosphorylation in Gαo-induced STAT3 
activation. 
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3. Methods 
3.1. Wild type (Wt) and S655 Phosphomutants APP-GFP cDNAs  
 APP cDNAs, S655 point mutated and fused to GFP (Green Fluorescent Protein) 
were already available at the lab. Briefly, human APP isoform 695 cDNA was used as a 
template to generate S655 cDNA point mutations, namely Serine 655 to Alanine 
(S655A) or to Glutamate (S655E), using site-directed mutagenesis. Due to their 
structure, these amino acids mimic a constitutively phosphorylated (Glutamate) and 
dephosphorylated (Alanine) S655. These mutants, together with parental Wt cDNA, 
were subcloned into the pEGFP-N1 vector (Clontech), a plasmid that encodes GFP. The  
result was a fusion gene of APP with GFP in its N-terminal (Vieira et al., 2009). 
 
3.2. Wt and Constitutively Active Gαo cDNAs  
 The human Gαo cDNAs were acquired from the Missouri S&T cDNA Resource 
Center. The Gαo subunit open reading frame (isoform Gαo-1) had been amplified from 
human whole brain cDNA (Clontech) by PCR and subcloned into pcDNA3.1+ vector 
(Invitrogen) between Kpn I (5') and Xba I (3') restriction sites. The Constitutively 
Active Gαo (Gαo CA) had been engineered by substituting Glutamine 205 by a Lysine 
(Q205L), using the Quickchange mutagenisis kit (Stratagene). This substitution 
significantly reduces the GTPase activity of Gαo, rendering it constitutively active. Both 
Gαo inserts have a size of 1070 bp.  
 
3.3. Gαo and constitutively active Gαo cDNAs amplification and 
purification 
 3.3.1. Bacterial transformation 
 E. Coli XL1-Blue competent cells were thawed on ice and 0,25 µg (5 µL) of Gαo 
and Gαo constitutively active cDNAs were each added to a 100 µl aliquot of competent 
cells. The cells were incubated on ice for 30 min. After this, they were subjected to an 
heat shock by incubation in a 42 ºC bath for 90 sec and then rapidly transferred to ice 
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for 2 min. 900 µl of SOC medium was added to the cells and a 45 min incubation at 37 
ºC followed. Finally, the cells were centrifuged at 14000 rpm for 30 sec, the supernatant 
was discarded and the pellet was resuspended in the remaining volume (100 µL), plated 
onto LB/ampicillin agar plates and incubated at 37 ºC during 16-18 h. 
	   	  
 3.3.2. MegaPrep DNA Purification  
 One colony of transformed bacteria with each Gαo cDNA was isolated and added 
to 3 mL of LB medium and incubated during 16-18 h at 37 ºC, with agitation. After 
bacterial growth, 1 mL of cells was transferred to 1 L of LB medium and again 
incubated overnight (O/N) at 37ºC with agitation. Cells were then centrifuged at 1500 x 
g, for 20 min (Beckman Avanti J-25 I - Beckman Coulter), the supernatant discarded 
and 30 mL of Cell Resuspension Solution was added. After resuspension, 30 mL of Cell 
Lysis Solution was added and mixed. After the solution became clear and viscous, 30 
mL of Neutralization Solution was added, mixed and centrifuged at 20000 x g for 15 
min. The supernatant was filtered using filter paper and the remaining volume was 
measured. 0,5 volume of isopropanol was added and then centrifuged at 14000 x g for 
15 min. The supernatant was discarded and the pellet was resuspended in 4 mL of 
sterile water. 20 mL of Wizard® Megapreps DNA Purification Resin was added to the 
solution and mixed. The mix was then transferred to a Megacolumn, inserted in a 
vacuum manifold port, and vacuum was applied. The column was then washed 2 times 
with Column Wash Solution, also by applying vacuum. 5 mL of ethanol 80% was added 
to the column and vacuum was applied. The column was then transferred to a 50 mL 
screw cap tube and centrifuged at 1300 x g for 5 min (Eppendorf Centrifuge 5810R). 
The liquid was discarded and the column was again placed in the vacuum manifold and 
dried by applying vacuum for 5 min. The column was then removed, placed in a new 50 
mL screw cap tube, and 3 mL of pre-heated (65-70 ºC) nuclease-free water was added 
to the column. After 1 min, the column was centrifuged at 1300 x g for 5 min, the liquid 
transferred to microcentrifuge tubes (400 µL per tube) and stored at -20 ºC. This 
procedure had been previously done in laboratory for the APP-GFPs cDNAs 
  
 3.3.3. Ethanol precipitation of plasmid DNA  
 Ethanol precipitation was also performed in order to increase DNA purification, 
which is essential for optimal transfections. 1/10 of sodium acetate was added to each 
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microcentrifuge tube containing the DNA solution. 2,5 volume of ethanol 100% was 
further added, mixed and incubated O/N at -20 ºC. After, the tubes were centrifuged 
(14000 x g, 15 min, 0 ºC), the supernatant discarded and 750 µL of ethanol 70% (half of 
the tube capacity) was added and mixed. The solutions were incubated during 5 min, at 
-20 ºC, and then centrifuged (14000 x g, 5 min, 0 ºC). The supernatant was discarded 
and the pellet was dried. After all traces of ethanol disappeared, the DNA in each tube 
was resuspended in 200 µL of sterile water and stored at -20ºC. 
 
3.4.  Culture and maintenance of the SH-SY5Y cell line 
 The SH-SY5Y human neuroblastoma cells are derived from the SK-N-SH cell 
line, originally established from a bone marrow biopsy of a neuroblastoma patient. The 
SH-SY5Y cells were maintained in a 10% FBS MEM:F12 (1:1) growth medium, in a 
5% CO2 humidified incubator at 37 ºC. Cells were divided when they reached 70-80% 
confluence, and transfected with the appropriated cDNAs as follows.  
  
3.5. Transfection of the SH-SY5Y cell line with APP-GFP and Gαo 
cDNAs 
 In order to be able to study the effects of APP phosphorylation and Gαo activity 
in cells, Wt and CA Gαo cDNAs, along with Wt, S655A and S655E APP-GFP cDNAs, 
were transfected into SH-SY5Y cells. Three different transfection reagents were first 
tested in order to optimize SH-SY5Y cells transfection: jetPRIME® (Polyplus-
transfection), TurboFectTM (Fermentas Life Sciences) and CombiMagTM (OZ 
Biosciences). For each of the reagents used, cells were seeded in 6-well plates 24 h 
before transfection, so that cells could be around 80 to 90% at the time of transfection. 
Also, the growth medium was changed immediately before the transfection procedure. 
  
 3.5.1. JetPRIME® transfection 
 The jetPRIME® transfection reagent is a molecule based on a non-liposomal 
formulation produced by Polyplus-transfectionTM. For each well, 1 µg of cDNA was 
diluted in 100 µL of jetPRIME® buffer. Then, 2 µL jetPRIME® reagent was added, 
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vortexed and the mix was incubated for 10 min at room temperature (RT). After this, 
the mixture was added to each well and mixed by gently agitating the plate. The cells 
were then incubated at 37 ºC in a 5% CO2 incubator. After 4 h, the cell medium was 
changed, and 24 h after transfection cells were collected in 250 µL 1% SDS for Western 
Blotting (WB). 
 
 3.5.2 TurboFectTM transfection 
 The TurboFectTM transfection reagent is a cationic polymer that forms a 
positively charged complex with DNA that is easily endocytosed by eukaryotic cells. 
Briefly, for each well, 1 µg of cDNA was diluted in 100 µL of serum-free growth 
medium. After gently vortexing it, 2 µL of TurboFectTM reagent was added to the DNA, 
mixed and incubated during 15 min at RT. It was then added to each well and mixed by 
gently agitating the plate. The cells were incubated at 37 ºC in a 5% CO2 incubator. 
After 6 h, the cell medium was changed, and at 24 h of total transfection time, cells 
were collected in 250 µL 1% SDS for WB. 
  
 3.5.3 CombiMagTM transfection 
 CombiMagTM transfection reagent is a solution containing magnetic particles 
that is used in combination with any other transfection reagent to improve its efficiency. 
In this case it was used in combination with TurboFectTM. It uses the principle of 
MagnetofectionTM, in which magnetic particles associate with vectors and then come 
into contact with cells by applying a magnetic force, thus enhancing the transfection 
efficiency (Scherer et al., 2002). First, for each well, 1 µL of CombiMagTM reagent was 
transferred to a microtube. Then, the TurboFectTM mixture was prepared by mixing 1 
µL of the reagent to 1 µg of DNA in a microtube containing 100 µL of serum-free 
growth medium. Without incubating, the mixture was transferred to the microtube 
containing the CombiMagTM and mixed by pipetting vigorously. It was then added to 
the cells mixed by gentle agitation of the plate. Finally, the 6-well plate was placed 
upon a magnetic plate (OZ Biosciences) and incubated for 15 min. Cells were further 
incubated at 37 ºC in a 5% CO2 incubator and the cell medium was changed after 6 h of 
transfection. 24 h after transfection cells were collected in 250 µL 1% SDS for WB. 
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3.6.  Cell collection and quantification of protein content  
Upon being collected in 250 µL 1% SDS, cells were immediately boiled at 90 ºC 
for 10 min, followed by a 20 sec sonication period, and stored at -20 ºC.  
Quantification of the protein content of the cell lysates was made using the 
Pierce's bicinchoninic acid (BCA) protein assay kit (Thermo Scientific). All the 
procedure was performed using a 96-well plate. The standard samples needed for 
quantification were prepared using increasing known amounts of bovine serum albumin 
(BSA), as depicted in Table 3. The remaining samples were prepared by mixing 5 µL of 
the cell lysate to 20 µL 1% SDS. 
 
Table 3 - Standards used in the BCA protein assay method. BSA, Bovine serum albumin solution (2 
mg/ml). 
Standard BSA (µL) 10% SDS (µL) H2O (µL) Protein mass (µg) 
Blank 0 2,5 22,5 0 
1 1 2,5 21,5 2 
2 2 2,5 20,5 4 
3 5 2,5 17,5 10 
4 10 2,5 12,5 20 
5 20 2,5 2,5 40 
 
The Working Reagent (W.R.) was prepared by mixing the BCA reagent A with 
the BCA reagent B in the proportion of 50:1, and 200 µL were added to each well. The 
plate was incubated during 30 min at 37 ºC, after which the absorbance at 562 nm was 
measured using a microplate reader (Infinite M200, Tecan). 
 
3.7. Antibodies  
There were several antibodies used in western blot assays. The primary 
antibodies were the 22C11 (Chemicon), directed against APP N-terminus, recognizing 
full-length APP, and thus enabling the evaluation of the transfection levels of the APP-
GFP cDNAs; anti-Gαo antibody (Upstate), for detecting Wt and CA Gαo transfection 
levels; both anti-actin N-terminal (Sigma) and anti-actin 2G2 (Acris antibodies) 
antibodies, and anti-β-tubulin (Invitrogen) antibody, for analysing the effects of Gαo and 
APP in cytoskeleton-related proteins. Another anti-Gαo antibody (Chemicon) was tested 
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but with no satisfactory results (see chapter 4.1). To evaluate the effect of Gαo and APP 
in STAT3 signalling two antibodies were used:  the monoclonal anti-phospho-STAT3 
(Millipore), directed against the phosphorylated Tyr705 residue, and the monoclonal 
anti-STAT3 (Cell Signalling Technology) antibodies, with both of them recognizing the 
alpha and beta STAT3 isoforms.  
 All the secondary antibodies, either recognizing mouse or rabbit antibodies, 
were goat antibodies labelled with horseradish peroxidase, purchased from Amersham 
Pharmacia. In Table 4 are represented the antibodies used, their respective dilutions and 
secondary antibody used. 
 
Table 4 - Antibodies used in the Western blots, respective target proteins and their sizes, and 
specific dilutions used. 
Target  
Protein/Epitope 
Size (kDa) Primary antibody Secondary antibody 
APP N-terminal 
109 and 115 
(endogenous); 139 and 
145 (exogenous) 
Monoclonal 22C11 
(Chemicon);  
Dilution: 1:250  
Horseradish Peroxidase 
conjugated α-Mouse IgG;  
Dilution: 1:5000 
Alpha subunit of 
Go protein 39  
Polyclonal Anti-Gαo 
(Upstate); 
Dilution: 1:5000 
Horseradish Peroxidase 
conjugated α-Rabbit IgG;  
Dilution: 1:5000 
Actin N-terminal 42  
Polyclonal Anti-actin 
N-terminal (Sigma); 
Dilution: 1:1000 
Horseradish Peroxidase 
conjugated α-Rabbit IgG  
Dilution: 1:500 
Pan actin 42  
Monoclonal Anti-
actin 2G2 (Acris); 
Dilution: 1:2000 
Horseradish Peroxidase 
conjugated α-Mouse IgG;  
Dilution: 1:5000 
β-tubulin 50  
Monoclonal 2-28-33 
(Invitrogen) 
Dilution: 1:2000 
Horseradish Peroxidase 
conjugated α-Mouse IgG  
Dilution: 1:5000 
Phospho-Tyr705 
of STAT3 76 and 84 
Monoclonal Anti-
phospho-STAT3 (Tyr 
705) (Millipore) 
Dilution: 1:3000 
Horseradish Peroxidase 
conjugated α-Rabbit IgG 
Dilution: 1:1000 
STAT3 76 and 84 
Monoclonal Anti-
STAT3 (124H6) (Cell 
Signaling) 
Dilution: 1:1000 
Horseradish Peroxidase 
conjugated α-Mouse IgG 
Dilution: 1:2000 
 
 
For the immunocytochemistry procedures, the rabbit polyclonal anti-Gαo and 
anti-APP 22C11 antibodies were used, together with the mouse monoclonal anti-STAT3 
(Cell Signaling). This antibody was used to analyze the influence of Gαo activation and 
APP phosphorylation in STAT3 signalling. Like in the WB, another anti-Gαo antibody 
(mouse monoclonal, Chemicon) was tested, again with no satisfactory results (Chapter 
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4.1). The list of the antibodies and their respective dilution and secondary antibody are 
present in Table 5. 
 
Table 5 - Antibodies used in immunocytochemistry, respective target proteins specific dilutions 
used. 
Target  
Protein/Epitope 
Primary antibody Secondary Antibody 
APP N-terminal 
Monoclonal 22C11 (Chemicon)  
Dilution: 1:50 
Alexa Fluor® 488 Goat Anti-
Mouse IgG (Life 
Technologies) Dilution: 1:300 
Alpha subunit of Go protein 
Polyclonal Anti-Gαo (Upstate) 
Dilution: 1:250 
Alexa Fluor® 594, 488 and 350 
Goat Anti-Rabbit IgG (Life 
Technologies) Dilution: 1:300 
STAT3 
Monoclonal Anti-STAT3 
(124H6) (Cell Signaling) 
Dilution: 1:450 
Texas Red®-X and Alexa 
Fluor® 350 goat anti-mouse IgG 
(Life Technologies) Dilution: 
1:300 
 
 
3.8. Western Blot assay 
 Mass-normalized cell lysates were subjected to electrophoresis on a 5-20% 
gradient sodium dodecylsulfate (SDS) polyacrylamide gel and then transferred to a 
nitrocellulose membrane. After transferring the proteins, the membranes were first 
soaped in 1X TBS for 10 min, and then the blockage of unspecific antibody binding 
sites was ensured by incubating the membrane for 1-2 h with 5% non-fat dry milk in 1X 
TBS-T solution. Incubation with the primary antibody was performed according to the 
manufacturer indications, or according to previous optimization experiments for the 
antibodies in use (the incubation time ranged from 2 h to O/N incubation). After 3 
washes with 1X TBS-T, the membranes were incubated for 2 h with the secondary 
antibody. All antibodies were diluted according to the manufacturer indications 
(dilutions used present in table 4), normally either in 3% non-fat dry milk in 1X TBS-T 
solution or in 3% BSA in 1X TBS-T solution. Membranes were additionally washed 3X 
with TBS-T and submitted to signal development using either a home made enhanced 
chemiluminescence (ECL) or LuminataTM Crescendo (Millipore) reagents. Both of the 
reagents work as a substrate to horseradish peroxidase with which the secondary 
antibodies are labelled, producing a chemiluminescent signal. In a dark room, the 
membranes were incubated for 1 min at RT with ECL or 5 min with LuminataTM 
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Crescendo, and then an autoradiography film was placed on top of the membrane and 
placed inside a film cassette. After the exposure (with time varying depending on the 
protein being detected), the film was developed in developing solution (Sigma Aldrich), 
washed in water and fixed in fixing solution (Sigma Aldrich). The membrane was 
further washed with 1x TBS-T and deionised water before drying. The autoradiograms 
were scanned in a GS-800 calibrated imaging densitometer (Bio-Rad) and protein bands 
quantified using the Quantity One densitometry software (Bio-Rad). 
 
3.9. Ponceau Red staining of protein bands 
 Ponceau Red staining is normally applied to assess successful electrotransfer of 
proteins to the membrane. However it can also be used as a loading control as an 
alternative to actin or β-tubulin, when these proteins vary with the experimental 
conditions. This type of staining has been described as a fast, inexpensive, and nontoxic 
method and it is fully reversible in a few minutes (Romero-Calvo et al., 2010).  
 The nitrocellulose membranes were incubated in Ponceau S solution (Sigma 
Aldrich) for seven min, followed by a wash with deionised water for making the protein 
bands clearly visible. The membrane was then scanned in a GS-800 calibrated imaging 
densitometer (Bio-rad). The membranes were then washed extensively with 1X TBS-T 
and water for completely removing the staining and thus be further used in WB assays.   
 
3.10. Immunocytochemistry assay 
 Cells grown on coverslips were fixed with a 4% paraformaldehyde PBS solution 
for 30 min, washed 3 times with PBS and permeabilized with a 0,2% TRITON PBS 
solution (10 min). After another 3 washes, the cells were covered with PBS 1X/3%BSA 
blockage solution for 30 min. The cells were then incubated with the primary antibodies 
diluted in PBS 1X/3%BSA (the respective dilutions are present in Table 5) for 2 h at 
RT. The antibodies were removed by washing 3 times with PBS and the specific 
secondary antibodies were incubated for 2 h at RT (see Table 5). After 3 washes with 
PBS and one with deionised water, the cells were mounted with VECTASHIELD® 
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mounting medium, with or without DAPI (Vector Laboratories). Fluorescence 
microscopy was carried out using a LSM 510 Meta confocal microscope (Zeiss). 
 
3.11. Image analysis 
 Every image analysis was performed using the ImageJ Fiji software. For STAT3 
nuclear intensity analysis, the nuclei were selected using the LiveWire plugin and 
STAT3 intensity was measured. To try to optimize the comparison between different 
conditions without the quantifications being affected by some fluorescence/antibody 
labelling issues (variation in noise, signal intensity), the signal intensity of STAT3 in 
the nuclei of transfected cells was divided by the signal intensity in the nuclei of non-
transfected cells (taken as control). Also, in every image, three measures of the 
background were performed and subtracted to the nuclei measure.  
 For colocalization analysis, the images were first processed using the 
DeconvolutionLab plugin for better removal of background noise and thus improving 
colocalization analysis (Landmann and Marbet, 2004). The colocalization analysis was 
conducted using the Coloc2 plugin. This plugin uses several pixel intensity spatial 
correlation methods to determine colocalization between two different colour channels, 
such as the Manders, the Costes, the Pearson or the Li methods. In the work here 
described, results were obtained using the Manders' method, since it is normally the 
most used when comparing two objects of different amounts (in this case two proteins 
who have different expression levels) (Manders et al., 1993). The results are presented 
as the percentage of colocalization of one protein with the other.  
 
3.12. Data analysis 
 Data is expressed as mean ± SEM (standard error of the mean) of the different 
experiments. Statistical significance analysis was conducted by one way analysis of 
variance (ANOVA) followed by the Turkey test. 
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4. Results 
 4.1. Optimization of the transfection method and 
antibodies dilutions 
 As described in chapter 3.4, three different transfection methods were first tested 
in order to choose which protocol should be use throughout the experiments. Cells were 
seeded in 6-well plates 24h before transfection and then transfected with Gαo Wt 
(henceforth called just Gαo) and Gαo CA for 24 hours using either jetPRIME®, 
TurboFectTM or CombiMagTM plus TurboFectTM transfection reagents. Gαo transfection 
levels were evaluated by Western Blot (WB) analysis using the polyclonal anti-Gαo 
antibody. As seen in Fig. 9, transfection of Go was detected in both TurboFectTM and 
CombiMagTM plus TurboFectTM transfected cells. While in Gαo CA there are not 
significant differences in the transfection levels, in Gαo there is a significant increase 
when using CombiMagTM plus TurboFectTM. TurboFectTM was chosen as the 
transfection reagent for further experiments for three reasons: 1) the signal was good 
enough to be detected during the following experiments and 2) overexpression of a 
given protein could affect its normal behavior inside the cell, leading to erroneous 
results; 3) CombiMagTM led to an increase in cellular apoptosis, as indicated by the 
higher amounts of cleaved PARP (an apoptosis indicator) in those lysates (Fig. 9). 
 
Two different antibodies against Gαo were acquired: a rabbit polyclonal antibody 
(Upstate) and a mouse monoclonal antibody (Chemicon). Both were tested in WB, with 
the first one working fine at a dilution of 1:5000 (recommended dilution being between 
1:2000 and 1:10000), as shown in Fig. 9, while the second one never gave a signal at 
Figure 9. Immunoblot analysis of Gαo transfection in SH-SY5Y using different transfection 
methods. Upper blot: WB performed with the polyclonal rabbit anti-Gαo antibody to analyze transfection 
levels. Lower blot: WB of the same lysates performed with an anti-cleaved PARP antibody to analyze 
cellular apoptosis. N-tx: non-transfected cells; jP: jetPRIME® mediated transfection; TF: TurboFectTM 
mediated transfection; CM+TF: CombiMagTM plus TurboFectTM mediated transfection.  
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  Goa Monoclonal	  Goa DAPI Merge
the various dilutions tested (started with the recommended 1:3000 dilution and 
concentrate it up to 1:500). While the company sent a substitute, the new one also didn´t 
work, but in this case it labelled a protein with a higher molecular weight than the one 
supposed for Gαo (data not shown). Both antibodies were also tested in 
immunocytochemistry (ICC) assays, with the polyclonal antibody exhibiting a pattern 
that was expected from Gαo, (e.g. presence at the plasma membrane), while the 
monoclonal antibody apparently was labelling a protein with a punctuate distribution 
throughout the cell (Fig. 10). 
 
 The antibodies against Phospho-STAT3 (P-STAT3) and STAT3 were also 
initially tested for WB and ICC applications. While the anti-STAT3 worked fine with 
the WB recommended dilution (1:1000), the anti-P-STAT3 gave a very dim signal 
(1:10000). Different dilutions were tested, with 1:3000 being the one that gave a more 
defined signal, and was thus used in the following WB experiments. For ICC 
applications, the recommended dilutions were effective: anti-STAT3 (1:400) and anti-P-
STAT3 (1:200). 
 
4.2. Effects of APP S655 phosphorylation and Gαo activation in 
APP/Gαo subcellular colocalization 
 As it has been previously reported and visualized in our lab, APP localizes 
mainly in the Golgi apparatus, with only a small fraction (less than 10%) being present 
Figure 10. Immunocytochemistry of SH-SY5Y cells transfected with pcDNA3. The anti-Gαo 
polyclonal antibody (1:250) was marked with a secondary antibody labelled with Alexa Fluor 488 
(green), while the anti-Gαo monoclonal antibody (1:250) was marked with a secondary antibody labelled 
with Texas Red. As expected, the polyclonal antibody marks a protein mainly present in the cell 
membrane, which is where Gαo is more abundant. On the contrary, the monoclonal antibody doesn't show 
the some kind of cellular distribution, indicating that it must be marking some protein other than Gαo. Bar: 
10 µm. 
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at the plasma membrane (PM) (Vieira et al., 2009; Vieira et al., 2010). On the other 
hand, Gαo is present across the entire cell, with predominance in the cytoplasmic face of 
the plasma membrane (Brabet et al., 1988; Gabrion et al., 1989). Since both proteins 
have been described to interact with each other, just downstream the 653YTSI656 APP 
domain, the effect of S655 phosphorylation in their interaction and subcellular 
colocalization was tested by cotransfecting SH-SY5Y cells with both Gαo cDNA and 
either Wt, S655A or S655E APP-GFPs cDNAs. Undifferentiated SH-SY5Y cells were 
transfected during a 6 h period, after which the coverslips were recovered and ICC was 
performed. All the APPs are fused to GFP (green channel), while Gαo was labelled with 
Alexa Fluor® 594 (red channel). 
 First, the distributions of Gαo and Gαo CA in 6h transfected cells were analysed. 
Endogenous Gαo, revealed by the anti-Gαo antibody, was mainly located at cells PM 
(where it is enriched) and in the cytoplasm (Fig. 11-A, vector transfected cells). 
Exogenous Gαo was highly located at the PM, slightly less at the cytoplasm (punctuated 
distribution) and, in cells expressing high levels of Gαo, this protein was found at what 
appeared to be the Golgi and nearby regions (Fig. 11-B, Gαo transfected cell). In 
comparison with Gαo, Gαo CA exhibits a similar PM/cytoplasm co-distribution, with 
enrichment at the PM, but leads to an increase in the number of projections (Fig. 11-C, 
Gαo CA transfected cells). Of note, with increasing levels of Gαo expression, its 
localization in the cytoplasm and Golgi increased, leading to a decrease in 
PM/cytoplasm localization ratio of Gαo. This was even more pronounced for Gαo CA 
transfected cells. 
 
 
A B C
Figure 11. Subcellular localization of Gαo. SH-SY5Y cells were labelled with anti-Gαo rabbit antibody.  
A) Cells transfected with pcDNA3; B) Cells transfected with Gαo; C) Cells transfected with Gαo CA. Bar: 
10 µm. 
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Figure 12. Gαo and APP subcellular colocalization. A) Cells cotransfected with Gαo and Wt APP-
GFP; B) Cells cotransfected with Gαo and SA APP-GFP; C) Cells cotransfected with Gαo and SE 
APP-GFP. Bar: 10 µm 
From the Wt APP-GFP/Gαo co-transfected images (Fig. 12-A) we could observe 
that Wt APP-GFP localizes mainly at the Golgi and ER and cytoplasmic vesicles, with 
the PM being only visible in some cells, and at few amounts. Again, exogenous Gαo was 
highly located at the PM, followed by the Golgi and the cytoplasm. The main sites of 
APP-GFP/Gαo colocalization were observed to be the Golgi and the PM, and, in some 
cells, in the PM of cells projections. While at the Golgi, APP-GFP/Gαo appear to 
actually co-localize, at the PM they appear to be juxtaposed (as expected). Of note, the 
great majority of APP-GFP vesicles does not colocalize with Gαo.  
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Besides this, even after the image processing prior to the colocalization analysis, 
the high expression of Gαo and its general distribution led to very elevated colocalization 
values between Gαo and APP-GFP, which may not correspond to real colocalization 
(Fig. 13). 
Relatively to the S655 phosphomutants, the microphotographs show that, 
apparently, there is no significant change in APP/Gαo colocalization when Gαo is 
cotransfected with either S655A or S655E APP-GFPs. However, both of them increase 
Gαo/APP-GFP colocalization when compared with the Wt APP-GFP (Fig. 12 and 13). A 
detailed analysis of the images reveals that the differences appeared to be due to an 
increased presence of APP-GFP in cellular projections. The colocalization analysis 
proved this to be true, especially for SA APP-GFP, where the differences were 
significant (Fig. 13).   
 
 The effect of Gαo activation in Gαo/APP-GFP colocalization was also studied. 
This time, the different APP-GFPs constructs were cotransfected with a constitutively 
active (CA) Gαo cDNA for 6 h. The same analysis procedure was performed as for 
APP/Gαo cotransfected cells, and the same problems arose, with Gαo CA high expression 
levels hindering the colocalization analysis. Nevertheless, comparative to APP-GFP/Gαo 
distribution, Gαo activation slightly increased Gαo/APP-GFP colocalization for both Wt 
Figure 13. Colocalization of Gαo with APP-GFP in the entire cotransfected cell and in its 
projections. The colocalization analysis was made in cotransfected cells with Gαo and either APP Wt, 
APP S655A (SA) or APP S655E (SE). In each cotransfected cell the analysis was performed in the 
entire cell or just by selecting its projections, if they were present. Only the differences between 
Gαo:APP Wt and either Gαo:APP SA or Gαo:APP SE were significant for the entire cell, and between 
Gαo:APP Wt and Gαo:APP SA for the cell projections. *p<0.05; **p<0.01; ***p<0.001. n=3, with each 
group containing 10 cells.  
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and SE APP-GFPs (compare Fig. 13 with Fig. 15). A more detailed analysis reveals that 
Gαo CA exhibits a similar PM/cytoplasm co-distribution that Gαo but, as it induces 
morphological alterations that result in higher PM surface area, it has a higher pool at 
the PM available to colocalize with APP-GFP, potentially explaining its higher 
colocalization with the Wt and SE APP-GFP proteins. All APP-GFP proteins colocalize 
with Gαo CA in the same subcellular structures as for Gαo: Golgi, PM and cellular 
projections (Fig. 14).  
 
Figure 14. Gαo CA and APP subcellular colocalization. A) Cells cotransfected with Gαo CA and 
Wt APP-GFP; B) Cells cotransfected with Gαo CA and SA APP-GFP; C) Cells cotransfected with 
Gαo CA and SE APP-GFP. Bar: 10 µm 
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 Since high expression of transfected Gαo made colocalization analysis difficult, 
we decided to do a qualitative Gαo and APP colocalization analysis in non-transfected 
cells. Immunocytochemistry was performed in SH-SY5Y cells using anti-Gαo  and 
22C11 (APP) antibodies. Results show that, indeed, potential colocalization sites occur 
at the PM and in what  appears to be the Golgi area (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Colocalization of Gαo CA with APP-GFP in the entire cell and in its projections. The 
colocalization analysis was made in cotransfected cells with Gαo CA and either APP Wt, APP SA or APP 
SE. In each cotransfected cell the analysis was performed in the entire cell or just by selecting its 
projections, if they were present. Each cotransfection was compared with either its Gαo counterpart: 
+p<0.05; ++p<0.01; +++p<0.001; or between APP-GFP constructs: *p<0.05; **p<0.01; ***p<0.001. n=3, 
with each group containing 10 cells.  
 
Figure 16. Subcellular localization of Gαo and APP in non-transfected SH-SY5Y. 
Gαo was labelled with anti-Gαo and APP was labelled with 22C11 antibody. Bar: 10 µm  
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4.3. Gαo/APP-induced alterations in cellular morphology  
 Both Go protein and APP have been implied (described?) in neuritogenesis and 
since they interact with each other, APP could be promoting neuritogenesis through Go 
activation. To study this hypothesis, and since some morphological changes were 
already seen in the microphotographs, the number of projections arising from cells was 
counted, in the  APP-GFP/Gαo and Gαo CA co-expressing cells. As control, the 
projections in non-transfected cells, pcDNA3, Gαo and Gαo CA transfected cells were 
also counted.  
 When Gαo was singly transfected, its overexpression significantly increased the 
number of projections when compared to non-transfected cells (~6 times). Moreover, all 
cotransfections were able to increase the number of projections in comparison with non-
transfected cells. In opposition, only Gαo  and its cotransfection with Wt APP-GFP 
increased the number of projections over the pcDN3 transfection. Interestingly, Gαo 
cotransfection with SA and SE APP-GFPs lead to a slight decrease in the number of 
projections when compared with Gαo alone (see Fig. 12 and 17). Interestingly, while not 
affecting the number of projections, SA and mainly SE APP-GFP seemed to lead to an 
increase in the projections length (Fig.12 and 14; results further ahead).    
  
  
 Regarding Gαo CA, and as already observed, its overexpression increased the 
number of projections when compared to Gαo (Fig. 11 and 18). However, when 
Figure 17. Number of projections per cell in SH-SY5Y cells. The number of projections was counted 
in non-transfected cells, pcDNA3 and Gαo-only transfected cells, and Gαo cotransfection with either Wt, 
SA or SE APP-GFP. Each transfection was compared to pcDNA3 transfected cells. *p<0.05; **p<0.01; 
***p<0.001. n=3, with each group containing 10 cells.  
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Figure 19. Percentage of cells with Pre-Neurites in SH-SY5Y non-transfected and transfected cells. 
The number of cells with pre-neurites was counted in non-transfected cells, pcDNA3 and Gαo-only 
transfected cells, and Gαo cotransfection with either Wt, SA or SE APP-GFP. Each transfection was 
compared to pcDNA3 transfected cells. *p<0.05; **p<0.01; ***p<0.001. n=3, with each group 
containing 10 cells.   
compared to Gαo, Gαo CA only significantly increased the number of projections in the 
SA APP-GFP cotransfections, while in the other cotransfections its effect was no 
different of Gαo (Fig. 14 and 18). Interestingly, the number of projections in Gαo CA and  
Gαo:Wt APP-GFP expressing cells is roughly the same, as for SA APP-GFP, while SE 
APP-GFP decrease their number by half (Fig. 17 and 18). 
  
 As mentioned earlier, while cotransfection with APP-GFP phosphomutants did 
not change the number of projections, it apparently led to an increased number of cells 
with longer projections (Fig. 12). Hence, we further scored the number of cells with 
projections longer than the cell body, typically named pre-neurites (PreN) (Fig. 19).  
	   
 
 
 
 
 
 
 
 
Figure 18. Number of projections per cell in SH-SY5Y cells. The number of projections was counted 
in non-transfected cells, pcDNA3, Gαo CA-only transfected cells and in cells cotransfected with Gαo CA 
and with either Wt, SA or SE APP-GFP. Each transfection was compared with either pcDNA3 transfected 
cells: *p<0.05; **p<0.01; ***p<0.001;  or with its Gαo counterpart: +p<0.05; ++p<0.01; +++p<0.001. n=3, 
with each group containing 10 cells. 
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 As seen in Fig. 19, indeed cotransfection of Gαo with SA and SE APP-GFPs 
increased the length of projections, without increasing their number. Wt APP-GFP, in 
its turn, is able to increase cellular projections but  it does not significantly alter their 
length. Gαo is not able to increase the number of cells with pre-neurites. 
 When transfected with Gαo CA, the number of cells with preN slightly increased 
over Gαo data, and the same occurred for the Wt APP-GFP/Gαo CA, when compared to 
Wt APP-GFP/Gαo cotransfected cells. However, probably due to the small size of the 
sample, these changes were not significant. In opposition to the Wt data, the number of 
cells bearing preN cotransfected with Gαo CA and SA or SE APP-GFP did not 
significantly change when compared to SA or SE APP-GFP/Gαo cotransfected cells 
(Fig. 20).  
	  
4.4. Analysis of cytoskeleton-related protein profiles 
 Since Gαo overexpression induced morphological changes, possible changes in 
cytoskeleton proteins, namely actin and tubulin, were evaluated. Cells were collected 
after 6 h of transfection and WB assay was performed (Fig. 21).  
  
  
 
Figure 20. Percentage of cells with Pre-Neurites in SH-SY5Y non-transfected and transfected cells. 
The number of cells with pre-neurites was counted in non-transfected cells, Gαo CA-only transfected cells 
and Gαo CA cotransfection with either Wt, SA or SE APP-GFP. Each Gαo CA transfection was compared 
with its Gαo counterpart. +p<0.05; ++p<0.01; +++p<0.001.  n=3, with each group containing 10 cells. 
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 Actin and Tubulin protein bands were quantified by densitometry, corrected to 
Ponceau relative levels, and plotted graphically (Fig. 22).	  
	  
  
 The results indicate that there is a high degree of variation in actin levels when 
transfected with either Gαo or APP-GFP cDNAs. There seems to exist a tendency for 
either Gαo or Gαo CA to decrease actin levels, while all forms of APP tend to increase it. 
When both proteins are cotransfected, there is also a tendency for actin to decrease.  
However, due to the high actin variability seen, these differences are not statistically 
significant. In general, tubulin levels tend to slightly decrease with Gαo or APP-GFPs 
transfections, but this is more accentuated for Gαo/APP-GFP cotransfections, and 
especially significant for Gαo/Gαo CA co-transfection with SA APP-GFP (Fig. 22).   
Figure 21. Immunoblot analysis of actin and tubulin levels in SH-SY5Y transfected cells. Besides 
WB of actin and tubulin, Gαo and APP were also visualized to confirm that they were successfully 
transfected and cotransfected. N1: pEGFP-N1 vector; pcDNA3: pcDNA3 vector.   
Figure 22. Evaluation of Actin and β-tubulin expression levels. Expression of actin and β-tubulin was 
evaluated after 6 h of transfection with different cDNAs. Each value was corrected using Ponceau Red 
staining as control, and plotted against the levels of its corresponding vector, taken as 1. *p<0.05; 
**p<0.01; ***p<0.001. n=5 
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4.5. Effects of APP in Gαo-induced STAT3 activation 
 4.5.1. Nuclear STAT3 changes in response to Gαo overexpression 
 One of the pathways already described by which Gαo leads to neurite growth is 
the STAT3 pathway (He et al., 2005).  To test the effect of APP in Gαo-induced STAT3 
activation, we first tested the effect of Gαo and Gαo CA in STAT3 signalling in SH-
SY5Y cells, in order to establish control conditions. Accordingly, we first intended to 
perform a double immunocytochemistry using the anti-Gαo mouse antibody to mark the 
transfected cells and the rabbit anti-P-STAT3 antibody to visualize STAT3 
phosphorylation levels, and thus STAT3 activation. However, as mentioned above the 
anti-Gαo mouse antibody never functioned (see chapter 4.1). Hence, for visualization of 
Gαo transfected cells we had to use the rabbit antibody, making it impossible to use at 
the same time the anti-P-STAT3 antibody. Since phosphorylation of STAT3 results in 
its dimerization and subsequent translocation to the nucleus (Sehgal, 2008), we  used 
the anti-STAT3 antibody instead and tried to indirectly measure STAT3 activation by 
measuring STAT3 nuclear intensity in transfected cells.  
 In our first experiment, SH-SY5Y cells were transfected with pcDNA3 vector, 
Gαo and Gαo CA cDNAs, and cells fixed upon 6 and 24 h of transfection. Double ICC 
was performed using polyclonal anti-Gαo and monoclonal anti-STAT3 antibodies, while 
the nucleus was labelled with DAPI (Fig. 23). 
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Figure 23. Nuclear STAT3 levels in Gαo expressing cells. A) Cells transfected with pcDNA3; B) Cells 
transfected with Gαo; C) Cells transfected with Gαo CA. ICC was performed after 6 h of transfection. Bar: 
10 µm.  
 
In pcDNA3 transfected cells we could observe medium and low endogenous Gαo 
levels, while in Gαo or Gαo CA transfected cells we also observe high levels of Gαo 
expression. This led us to divide the cells into three categories: low, medium and 
high/transfected Gαo cells. Nuclear STAT3 (nSTAT3) mean intensity was measured in 
all these cell categories and compared between them (Fig. 24-A). Also, for a better 
comparison between different conditions, the mean intensities of nSTAT3 in cells 
exhibiting medium and high/transfected Gαo/Gαo CA levels were further compared to 
mean intensities of neighbour cells with low Gαo levels, taken as 1. This allowed 
minimizing the influence of fluorescence differences between different transfection 
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conditions (Fig. 24-B).  All images were analysed using Fiji, with DAPI labelling being 
used to delimit the nuclear area. 
   
	  
	  
	  
	  
	  
 
  
  
 
 
 
 
 
  
 
 
 
 
 
 The results show that cells that appear to have been transfected with either Gαo 
or Gαo CA have higher nSTAT3 intensity than non-transfected cells at 6 h. However, at 
24 h, these levels have decreased and equalled the ones of cells expressing low levels of 
Gαo. Interestingly, cells that appear to be expressing medium levels of endogenous Gαo 
(‘medium Gαo cells’) have lower nuclear STAT3 intensity, with this being clearly 
visible in the microphotographs (Fig. 23).  
 The time point of 6 h of transfection was chosen from the results of a previous 
WB assay where several Gαo transfection times were tested for STAT3 activation. As 
seen in Fig. 25, P-STAT3 levels were higher (when compared to pcDNA3 vector) at 6h, 
and this time point was therefore confirmed to be the appropriated to study the effects of 
APP on Gαo-induced STAT3 activation (Fig. 25).  
Figure 24. Nuclear STAT3 mean intensity. A) Raw nSTAT3 mean intensity in pcDNA3, Gαo and 
Gαo CA transfected cells. B) Comparison between nSTAT3 mean intensity of cells with 
medium/high Gαo expression and the nSTAT3 intensity of cells expressing low Gαo levels (taken as 
1). n=1 where 30 cells were evaluated  
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Further and of some importance, while in the WB we could only detect the 
STAT3 activation phase for Gαo and at 6h, for the other time points on, and for all the 
Gαo CA lysates, we could only detect a downregulation phase following activation (Fig 
25). This inhibiting phase correlated very well with the equal and lower levels of 
nSTAT3 of cells expressing high and medium amounts of Gαo at 24h (Fig. 24, 24h). 
Hence, higher nSTAT3 targeting above non-transfected cells levels is a good method to 
visualize immediate Gαo-induced STAT3 activation, while lower nSTAT3 targeting, 
below non-transfected cells levels appears to correlate with a down regulation phase 
following Gαo-induced STAT3 activation (Fig. 24-B). This is corroborated by findings 
from our group where this retroinhibition mechanism is accompanied by severe 
decrease in Gαo levels, as it may occur in the medium-expressing cells. 
 
4.5.2. APP phosphorylation influences Gαo-induced STAT3 activation 
 The next step was to see if APP phosphorylation influenced STAT3 activation 
induced by Gαo overexpression. Undifferentiated SH-SY5Y cells were cotransfected for 
6 h, after which cells were fixed and ICC was performed: cells were labelled with green 
fluorescing APP-GFP, red fluorescing Gαo (labelled with Alexa Fluor® 594) and blue 
fluorescing STAT3 (labelled with Alexa Fluor® 350) (Fig 26 and 27). Of note, in this 
ICC the mounting media containing DAPI could not be used. Thus, to evaluate the 
nuclear STAT3 levels in cotransfected cells, a qualitatively analysis was performed in 
two ways: 1) by visually comparing nuclear STAT3 levels in cotransfected cells and in 
the surrounding non-transfected cells, and 2) comparing the distribution of STAT3 
levels between the nuclei (depicted by APP-GFP labelling) and the cytoplasm of 
cotransfected cells. The nuclear STAT3 levels were so divided in three categories: 
lower, equal and higher nSTAT3 (Fig. 28).  
Figure 25. Immunoblot analysis of Phospho-STAT3 (upper blot) and STAT3 (medium blot) levels 
at several hours of transfection with pcDNA3, Gαo or Gαo CA cDNAs ( Gαo expression in lower blot).   
SACS/UA	  2012	  
50	   	   Roberto	  Alexandre	  dos	  Santos	  Dias	  
Figure 26. Analysis of nuclear STAT3 levels in APP-GFP and Gαo transfected cells. A) Cells 
cotransfected with Gαo and Wt APP-GFP; B) Cells cotransfected with Gαo and SA APP-GFP; C) Cells 
cotransfected with Gαo and SE APP-GFP. Bar: 10 µm 
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Figure 27. Analysis of nuclear STAT3 levels in APP-GFP and Gαo CA transfected cells. A) Cells 
cotransfected with Gαo CA and Wt APP-GFP; B) Cells cotransfected with Gαo CA and SA APP-GFP; C) 
Cells cotransfected with Gαo CA and SE APP-GFP. Bar: 10 µm 
 
  
 
 
 
 
 
 
 
 
 
 The results seem to indicate that cotransfection with APP-GFPs constructs leads 
to a decrease in Gαo-induced STAT3 activation (or increase in a retro-inhibition 
mechanism upon STAT3 activation), since there is a higher cell percentage with equal 
or lower levels of nSTAT3 than higher levels. While not being statistically significant, 
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Figure 28. Qualitative analysis of nuclear STAT3 levels in APP/Gαo cotransfected cells by 
comparison of nuclear STAT intensity of cotransfected versus neighbour non-transfected cells. A) 
nSTAT3 levels in cotransfected cells with Gαo and either Wt, SA or SE APP-GFP. B) nSTAT3 levels in 
cotransfected cells with Gαo CA and either Wt, SA or SE APP-GFP. Each Gαo CA transfection was 
compared with its Gαo counterpart. +p<0.05; ++p<0.01; +++p<0.001. n=3, with each group containing 10 
cells. 
this phenomenon appears to be more pronounced when Gαo is cotransfected with SE 
APP-GFP, and less for Gαo:Wt APP-GFP cotransfection (higher number of cells with 
increased nSTAT3) (Fig. 28-A).    
 As seen in Figure 28-B, cotransfections with Gαo CA led to a shift of the 
nSTAT3 intensity profiles to the right (more activation) for the Wt and SA APP-GFP, 
while leading to a shift for the left for the SE APP-GFP mutant (more inactivation). 
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The problem with this analysis is that being qualitative, it makes comparisons 
with the previous experiment difficult to perform, so one has to be careful when 
drawing conclusions from these results. In order to try to overcome this problem, a 
quantitative analysis was also performed. However, as it was previously mentioned, 
without DAPI to indentify the nuclei we had to use the APP-GFP labelling to delimit 
the nuclei in transfected cells, while on non-transfected cells the centre of the cell body 
was manually selected. Fortunately, in most cases it was easy to see the location of the 
nucleus since there was a significant increase or decrease in non-transfected nSTAT3. 
 The mean intensity was first measured in transfected cells and compared 
between conditions (Fig. 29). The results show a pattern similar to the qualitative 
analysis, with APP phosphomutants generally showing lower nSTAT3 levels when 
compared with Wt APP-GFP, in Gαo cotransfections, and with Gαo CA being able to 
increase the levels of nSTAT3 when cotransfected with SA APP-GFP, while decreasing 
nSTAT3 levels for the SE mutant.  
 
	   	    
Figure 29. Quantitative analysis of Nuclear STAT3 levels in Gαo/APP-GFP cotransfected cells. 
nSTAT3 mean intensity in cotransfected cells. *: comparison performed in Gαo cotransfected cells 
between Wt APP-GFP and SA or SE APP-GFP; +: comparison between Gαo CA and Gαo cotransfected 
cells. *p<0.05; **p<0.01; ***p<0.001. n=3, with each group containing 10 cells. 
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5. Discussion 
	   With this work we intended to study cellular interactions between APP and Gαo 
proteins, namely their subcellular colocalization, their capability of inducing neurite 
outgrowth and activating the STAT3 pathway, together with the effect of APP 
phosphorylation and Gαo activation in those processes. 
  
 We first determined that the TurboFectTM transfection reagent was the most 
suitable for our experiments. While jetPRIME didn't induce any significant transfection, 
both TurboFectTM and the combination of TurboFectTM with CombiMagTM were able to 
induce transfection of both Gαo and Gαo CA cDNAs. TurboFectTM was chosen over 
CombiMagTM plus TurboFectTM because the latter, although inducing a higher 
transfection rate, also led to increased apoptosis, measured via the amount of cleaved 
PARP (Fig. 9). Also, in previous work conducted in the lab, TurboFectTM was used to 
transfect APP-GFP cDNAs in SH-SY5Y cells with satisfactory results (Rocha, 2011). 
   
 Following, we observed the SH-SY5Y subcellular sites of Gαo and Gαo CA 
localization (Fig. 11). Almost no differences could be observed between endogenous 
and exogenous Gαo or Gαo CA subcellular distributions, but a more detailed observation 
showed that increasing the amounts of Gαo by Gαo or Gαo CA transfection lead to an 
increase in its signal in the cytoplasm area (cytoplasm plus Golgi). Further, this increase 
appeared to be even slightly higher for exogenous Gαo CA than for exogenous Gαo. 
Nonetheless, this has to be further proved, by e.g. determining the PM-to-cytoplasm 
distribution ratio for each condition.  
Next, we determined the subcellular colocalization sites for Wt, SA and SE 
APP-GFP with both Gαo and Gαo CA proteins. All the cotransfections were performed 
during the course of 6 h, since A) this was a time period when both proteins started to 
be expressed, and could be visually observed, and B) it was the only time point where 
Gαo-induced STAT3 phosphorylation could be observed by WB means (see chapter 
4.5.1). The images showed that APP-GFP proteins and transfected Gαo mainly 
colocalized at the PM, including in cellular projections, and at the Golgi and nearby 
cytoplasmic vesicles (Fig. 12). The quantitative analysis of the entire cell using Coloc2 
plugin of Fiji showed that colocalization with Gαo was slightly higher for both SA and 
SE APP-GFPs when compared to Wt APP-GFP (Fig. 13). By analysing the cells 
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images, this difference in colocalization appeared to be more pronounced at the cellular 
projections. Quantitative colocalization analysis of these projections proved this to be 
true (statistically significant) only for the SA and not for the SE APP-GFP mutant (Fig. 
13). A more careful examination of the cells images revealed that the Gαo localization is 
not itself altered, but that the APP S655 phosphomutants appear to localize, at a higher 
extent than the Wt APP-GFP, in subcellular sites where they can interact with Gαo. For 
example, and as it was already reported, both APP-GFPs phosphomutants are more 
enriched in the PM (Vieira et al., 2009). Since Gαo is mainly localized in the PM, it is 
normal that both phosphomutants present higher colocalization with Gαo. Further, both 
mutants spend also more time at the Golgi than the Wt APP-GFP (Vieira et al., 2009; 
Vieira et al., 2010), another structure where exogenous Gαo was also found enriched 
(Fig. 12).  
 Mimicking Gαo activation using the Gαo CA mutant resulted in only a slight 
increase in Gαo/APP colocalization, and only for Wt (from 65% to 70%) and SE APP-
GFPs (from 72% to 77%). Again, we could not observe an alteration in APP-GFP 
proteins subcellular localization with their cotransfection with constitutively active Gαo 
(Fig. 14). One hypothesis arises to explain this slightly higher colocalization: with 
activation, α subunits of heterotrimeric G proteins dissociate from the βγ subunit and 
from the respective GPCR so they are available to interact with their effector proteins, 
which may be localized inside the cell and not at the plasma membrane (Svoboda and 
Novotny, 2002; Hynes et al., 2004). This means increased Gαo CA distribution 
throughout the cell, increasing the probability of APP and Gαo to colocalize. This should 
be especially true for SE APP-GFP, since this mutant has an increased trafficking across 
the cell, in opposition to the SA mutant, which exits more difficultly from the PM and 
Golgi (Vieira et al., 2009).  
 Of note, all this colocalization data has to be interpreted with some caution, 
since exogenous Gαo appears to have a higher expression than APP-GFP, and since it is 
more widely distributed throughout the cell, the quantitative analysis yielded very high 
colocalization levels between both proteins, which probably does not all correspond to 
true colocalization. Besides projections, some cytoplasmic vesicles and the Golgi, it 
does not seem to exist true colocalization between Gαo and APP in the remaining 
subcellular locations. The same occurs with Gαo CA, which is highly expressed in 
cotransfected cells, causing the same problems with the colocalization analysis, yielding 
higher values than we would expect for true colocalization. Future work that could shed 
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more light on the effect of APP phosphorylation on Gαo/APP colocalization will be to 
analyse the colocalization of APP-GFP proteins with the endogenous Gαo. This way, Gαo 
expression should not be so high and thus colocalization analysis would be closer to the 
reality. Indeed, in order to better analyse potential sites of endogenous APP/Gαo 
colocalization, this was observed in non-transfected cells by ICC means. Results 
showed that endogenous APP and endogenous Gαo distributions are quite exclusive, 
with the PM being the main visible site of potential colocalization, while some 
colocalization appears to also occur nearby the Golgi (Fig. 16).  
 
 Interestingly, in these non-transfected cells labelled with anti-Gαo and 22C11, it 
was possible to observe that cells with more projections were expressing more Gαo (data 
not shown). Further, a previous study conducted in our lab showed that, upon 24h of 
transfection, APP-GFP not only slightly increased the number of processes in SH-
SY5Y, but also increased their length, specially for the SE APP-GFP protein, with over 
50% of transfected cells exhibiting pre-neurites (contrasting with less than 20% in N1 
vector transfected cells) (Rocha, 2011). So, the next goal was to analyse if Gαo/APP co-
transfection induced morphological changes in SH-SY5Y cells, and if these were 
affected by S655 phosphorylation and Gαo activation.  
 First, non-transfected cells and pcDNA3 transfected cells were analysed to 
establish a control. As expected in undifferentiated SH-SY5Y cells, very few 
projections were visible (≈ 1 per cell), while transfection of the vector pcDNA3 alone 
increased this to ≈ 3 per cell (Fig. 17). When transfected with Gαo, the number of 
projections increased significantly (doubled) relatively to vector-transfected cells, and 
most of the cells appeared highly plastic, with very small projections. This increased 
even more when Gαo was cotransfected with Wt APP-GFP but, unexpectedly, decreased 
when it was cotransfected with either the SA APP-GFP or SE APP-GFP proteins (Fig. 
17), what was intriguing since their higher colocalization (Fig. 13). By its turn, Gαo 
activation alone, mimicked by the Gαo CA, also increased the number of projections 
over Gαo data (Fig. 18). However, the number of projections did not change for Gαo CA 
cotransfection with Wt or SE APP when compared to their Gαo respective transfections 
(Fig. 18). Since the number of projections in Gαo CA and Gαo:Wt APP-GFP expressing 
cells is roughly the same, and  Wt APP-GFP cotransfection with  Gαo CA does not 
increase it, this indicates that APP cooperates with Gαo to increase the number of 
projections most probably via Gαo activation. Interestingly, Gαo CA:SA APP-GFP 
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cotransfection doubles the number of projections found in Gαo:SA APP-GFP cells, but 
not above Gαo CA alone, indicating that SA is not able to activate Gαo or to alone direct 
it to a downstream pathway leading to the generation of projections. Nonetheless, SA 
APP-GFP does not hinder activated Gαo (Gαo CA) to follow that pathway, a 
phenomenon that actually occurs with the S655E APP-GFP mutant (Gαo and Gαo CA 
transfections had fewer projections). This mutant inhibits normal Gαo CA-induction of 
projections, potentially deviating it for other processes. Indeed, subsequent analysis 
confirmed that although both S655 phosphomutants did not increase the number of 
projections, they increased their length, as it could be seen in the microphotographs 
(Fig. 12 and 14) and by the increased number of cells with pre-neurites (Fig. 19 and 20). 
Interestingly, this finding correlates well with their higher colocalization with Gαo at the 
PM/cellular projections (Fig. 13 and 15). Noticeably, this elongation was longer for the 
Gαo/SE co-transfection: more cells with pre-neurites and visually longer pre-neurites. 
Moreover, for Gαo CA, only when transfected alone or cotransfected with Wt APP-GFP 
we see a slight increase in the number of cells with pre-neurites when compared to Gαo. 
This occurred with a much lower amplitude than the observed for the number of 
projections, indicating that activated Gαo is more prone to activate the formation of 
cellular projections rather than neuritic elongation. In opposition to Wt APP-GFP, Gαo 
CA cotransfection with the S655 phosphomutants does not change or even slightly 
decreases (S655A) neuritic elongation. All these suggest a hypothesis where, when at 
the PM (or specifically in projections), APP binds to and targets Gαo to a complex with 
other proteins that function in neuritic elongation. The binding strength of this cell 
surface APP/Gαo containing complex would be highly increased by APP S655 
phosphorylation, which would ‘sequestrate’ active Gαo and target it to elongation. 
Dephospho S655 APP could also forms this complex at the PM but, if Gαo is already 
activated, APP would not be able to ‘lock it’ in the elongation complex/pathway, and 
part of activated Gαo (as it occurs with Gαo CA) would enter the alternative pathway of 
formation of projections.  
In synthesis, these results show that, after short-term transfection, both proteins 
are important for neuritogenesis, either in for de novo formation of neurites or for 
neuritic elongation. Activated Gαo appears to be very important in the initial 
cytoskeleton modifications, such as the increase in the number of projections, with APP 
co-stimulating it, potentially by increasing Gαo activation. Colocalization at the PM 
and/or at cells projections is not the most important for co-stimulation of the number of 
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projections. By its turn, APP is very important for the elongation of the projections, 
with Gαo cooperating with APP potentially via the formation of a phospho S655 
APP/Gαo complex with an unknown protein, such as GAP-43 and/or GRIN1. Another 
player of this mechanism can be sAPPα, a known neuritogenic factor, whose secretion 
is increased by S655 phosphorylation (Young-Pearse et al., 2008; Vieira et al., 2009). 
Of note, not only sAPPα but also membranar APP is necessary for neuritic elongation 
(Young-Pearse et al., 2008), and thus the higher cell surface locations for the S655 
phosphomutants may underlie part of the mechanisms observed for their higher neuritic 
elongation. Remarkably, since SA normally does not elongate projections more than the 
Wt, this work places Gαo in this membranar APP/sAPP neuritogenic mechanism. 
However, with these results it is still unclear if both proteins interact directly 
with each other or if they stimulate each other pathway at more downstream (or 
upstream) levels. The formation of APP/Gαo and APP/Gαo/GRIN1 or GAP43 complexes 
and their colocalization at the PM will be very interesting to analyse.  
  
 Cytoskeleton proteins remodelling is an important step in the formation and 
stabilization of neurites (da Silva and Dotti, 2002). With that in mind, we analysed the 
expression of both tubulin and actin to see if Gαo or APP overexpression modified their 
levels. While there seems to exist a tendency to either Gαo or Gαo CA to decrease actin 
levels, and for all APP-GFP forms to increase it, what is more predominant is the high 
variability that exists between experiments (high standard error of the mean), with the 
same occurring for tubulin levels. Since actin and tubulin are normally very tightly 
controlled proteins, even with their β-isoforms being often used as loading controls, 
these great variations seem to indicate a high level of actin and microtubule remodelling 
occurring in the transfected cells, which agrees with the high number of projections 
induced by Gαo and/or APP expression, and/or their elongation. This remodelling is 
more pronounced when both proteins are cotransfected, corroborating with the findings 
that these proteins can cooperate in cytoskeleton remodelling.  
 
 Until this point we have already shown that APP and Gαo are responsible for 
several morphological changes resulting in neuritogenesis. Following, we went to test if 
these morphological changes could be related to Gαo-induced STAT3 activation, but this 
was somewhat difficult, due to the existence of what appears to be a retro-inhibition 
mechanism. When cells were transfected for 6h with only Gαo or Gαo CA, a rise in 
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nuclear STAT3 levels was visible, indicating that indeed Gαo was capable of inducing 
STAT3 activation (Fig. 23 and 24). These results were also confirmed by WB assay 
(Fig. 25) although only for Gαo, with no increases but rather decreases below control 
levels being observed for P-STAT3 upon Gαo CA transfection. Since Gαo CA is reported 
to increase P-STAT3 levels (Ram et al., 2000) this revealed that, following Gαo/STAT3 
activation, a retro-inhibition mechanism rapidly occurs. Indeed, this retro-inhibition is 
visible by ICC upon 24 h of transfection, where nSTAT3 levels had returned to levels 
equal or lower than in neighbour non-transfected cells. When phosphorylated, STAT3 
dimerizes and is translocated to the nucleus, where it binds to DNA and acts as a 
transcriptional factor. However, this action is normally short-lived, with STAT3 being 
dephosphorylated only 15-30 min after entering the nucleus, which results in its export 
to the cytoplasm. For STAT3 signalling to be maintained, STAT3 must be continuous 
phosphorylated in the cytoplasm and shuttled to the nucleus (Pranada et al., 2004; 
Vinkemeier, 2004). In our experiment we are only seeing STAT3 accumulation in the 
nucleus upon 6 h of transfection, with the signalling almost disappearing at 24 h. This is 
not unique, since in most cases, STAT3 signalling is transient and involves retro-
inhibition mechanisms (Schuringa, 2001). Some factors involved in this feedback have 
already been identified, such as the suppressors of cytokine signalling (SOCS) proteins, 
which are transcribed as a result of STAT3 activation, or by the action of protein 
phosphatases (Nicola and Greenhalgh, 2000; Tanuma et al., 2000). However, these 
proteins have only being described to interact with Jak/STAT signalling, so it is unclear 
if they are responsible for the retro-inhibition mechanism we are observing in our 
conditions. 
 When co-transfected with APP-GFP constructs, Gαo did not seem to activate 
STAT3, with all cotransfections mainly leading to lower or equal nSTAT3 intensities 
(qualitative analysis). Nonetheless, some activation was still visible, mainly for the Wt, 
correlating with its role in formation of projections, as it also increased when Gαo CA 
was cotransfected (Fig. 28). In contrast, Gαo cotransfection with SA and SE have lower 
induction of nSTAT3 levels (especially for SE), as depicted from qualitative and 
quantitative data. But while SA increases nSTAT3 intensity when cotransfected with 
Gαo CA, SE does not change or even decreases (Fig. 28 and 29). These results can either 
mean that A) APP is blocking Gαo-induced STAT3 activation, or B) APP is accelerating 
Gαo-induced STAT3 activation and consequent deactivation. We believe that the 
hypothesis B is the correct one, due to the morphological changes that are enhanced 
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when Gαo is cotransfected with APP and because, as seen by the qualitative analysis, 
there are still a few cells, even when APP SE is cotransfected, that exhibit high levels of 
nSTAT3. Another work being developed in our lab addressed this theme by analysing 
STAT3 Tyr705 phosphorylation in WB assays, and results showed a more pronounced 
Gαo-induced STAT3 activation however, with cotransfection of APP constructs with 
either Gαo or Gαo CA, this activation decreased, consistent with the existence of a retro-
inhibition effect (data not yet published).  Also, recent studies indicate that sAPPα is 
able to induce STAT3 activation through the IL-6/gp130 signalling pathway, in 
alternative to the Src-Stat3 pathway activated by Gαo (Kwak et al., 2010). Since 
phosphorylation of S655 induces a higher production of sAPPα (Vieira et al., 2009), 
retro-inhibition following a faster/greater STAT3 activation would explain why cells 
co-transfected with SE APP-GFP  and Gαo CA showed the lowest number of high 
nSTAT3 and the highest of lower nSTAT3. 
Interestingly, the profiles of nSTAT3 intensities with APP-GFP and Gαo co-
transfections (Fig. 28 and 29) correlate well with the profiles of number of projections 
(Fig. 17 and 18). Further, the cotransfection with longer neurites (SE/Gαo) leads to the 
highest nSTAT3 retro-inhibition, suggesting a correlation between neuritic elongation 
and a pre-activated and already retro-inhibited STAT3 signalling. Also, besides STAT3, 
there is a possibility that both Gαo and APP are activating other neuritogenic pathways. 
As been already mentioned, Gαo has also been shown to induce neuritogenesis through 
interaction with GRIN1, which leads to activation of cdc42, a member of the Rho 
family of GTPases (Nakata and Kozasa, 2005). Moreover, sAPPα has been described as 
an inducer of neuritogenesis through the activation of the mitogen-activated protein 
kinase (MAPK) pathway (Gakhar-Koppole et al., 2008).  
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6. Conclusion 
 This work provided evidences that Gαo and APP are important for inducing 
morphological alterations related to neuritogenesis, with Gαo having an essential role in 
inducing the initial formation of cellular projections, probably by activating the STAT3 
pathway, and APP being important for their elongation. APP was observed to highly 
cooperate with Gαo in the formation of cellular projections, most probably via Gαo 
activation, while Gαo appears to be a part of an alternative APP-dependent neuritic 
elongation mechanism, enhanced by APP S655 phosphorylation. However, their 
interactive play in these mechanisms still need further clarification, including the role 
played by APP and its phosphorylation in Gαo-induced neuritogenesis and STAT3 
activation. Further work will comprehend e.g. the morphological evaluation of a higher 
number of cells to certify these findings, the analysis of STAT3 activation by ICC using 
APP-GFP, a mouse anti-Gαo antibody and the rabbit anti-P-STAT3 antibody, and the 
analysis of relevant APP/Gαo complexes and other neuritogenic pathways that may be 
being influenced by APP and Gαo activity. These results prove that these proteins 
functionally interact, and their potential value in neuritogenic therapeutic applications 
will be further studied. 
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Appendix 
cDNA amplification and purification solutions 
Luria-Bertani (LB) growth medium with Ampicillin: 
  For a final volume of 1 L, dissolve 25 g of LB (Merck) in deionised water. 
Adjust the volume up to 1 L of deionised water and autoclave the solution (the LB will 
mix during autoclaving). Let the medium cool down to 60ºC and add 1 mL of ampicillin 
of a 50 mg/mL stock solution. 
 
Super Optimal broth with Catabolite repression (SOC) medium: 
For a final volume of 1 L, dissolve 25,5g of SOB broth (Sigma-Aldrich) in 
deionised water. Shake until the solute is dissolved, add 10 mL of 250 mM KCL 
solution, adjust the pH to 7.0 with 5 N of sodium hydroxide and adjust the final volume 
up to 1 L with deionised water. Sterilize by autoclaving, cool it down to about 60ºC and 
add 20 mL of a sterile 1M glucose solution.  
 
Cell Resuspension Solution: 
 - 50 mM of Tris-HCl (pH 7,5) 
 - 10 mM of EDTA 
 - 100 µg/mL of RNase A 
 
Cell Lysis Solution:  
 - 0.2 M of sodium hydroxide 
 - 1% of SDS 
 
Neutralization Solution:  
 - 1.32 M of potassium acetate (pH 4.8) 
  
Neutralization Solution:  
 - 80 mM of potassium acetate 
 - 8.3 mM of Tris-HCl (pH 7.5) 
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 - 40 µM of EDTA 
 - 55% of ethanol 
 
Cell Culture and Immunocytochemistry Solutions 
PBS (1x):  
For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Pierce) in deionised water. Final composition:  
-  8 mM Sodium Phosphate  
-  2 mM Potassium Phosphate  
-  140 mM Sodium Chloride  
-  10 mM Potassim Chloride 
 Sterilize by filtering the solution through a 0,2 µm filter and store it at 4ºC. 
 
10% FBS MEM:F12 (1:1): 
 For a final volume of 1 L dissolve the next substances in deionised water: 
 - 4,805 g of MEM (Gibco, Invitrogen)  
 - 5,315 g of F12 (Gibco, Invitrogen)  
 - 1,5 g of NaHCO3 (Sigma) 
 - 0,055 g of Sodium pyruvate (Sigma)  
 - 10 mL of Streptomycin/Penicillin/Amphotericin solution (Gibco, Invitrogen) 
 - 100 mL of 10% FBS (Gibco, Invitrogen)  
 - 2,5 mL of L-glutamine (200 mM stock solution) 
 Adjust the pH to 7,3 and then adjust the volume to 1 L with deionised water. 
  
4% Paraformaldehyde: 
 For a final volume of 100 mL, dissolve 4 g of paraformaldehyde in 100 mL of 
PBS 1X. Boil the solution at 58ºC, add a few drops of 1M sodium hydroxide for a better  
dissolution of the paraformaldehyde (only if necessary) and filter the final solution. 
Store at RT, away from light sources.  
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SDS-PAGE and Western Blot solutions 
Lower Gel Buffer (LGB) 4x: 
 To a final volume of 1 L, add to deionised water the following: 
 - 181,65 g of Tris (1,5 M) 
 - 4 g of SDS (0,4%) 
 Mix to solve the solutes, adjust the pH to 8.9 and the volume to 1 L with 
deionised water. Store at 4ºC. 
 
Upper Gel Buffer (UGB) 5x: 
 To a final volume of 1 L, add to deionised water: 
 - 75,69 g of Tris (0,5 M) 
 Mix to solve the solutes, adjust the pH to 6.8 and the volume to 1 L with 
deionised water. Store at 4ºC. 
 
30% Acrylamide/0,8% Bisacrylamide: 
 To a final volume of 100 mL, add to deionised water the following:  
 - 29,2 g of Acrylamide  
 -0,8 g of Bisacrylamide  
 Mix to solve the solutes, adjust the volume to 100 mL with deionised water and 
filter trhough a 0,2 µm filter. Store at 4ºC. 
  
10% ammonium persulfate (APS): 
 Right before use, dissolve 1 g of APS in 10 mL of deionised water. 
 
10% sodium dodecylsulfate (SDS): 
 Dissolve 1 g of SDS in 10 ml of deionised water.  
 
1 M Tris solution (pH 6.8): 
 To a final volume of 250 mL, add to deionised water: 
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 - 30,3 g of Tris base 
 Adjust the pH to 6.8 and the volume to 250 mL. 
 
Loading Gel Buffer (4x): 
 Mix the following reagents: 
 - 2,5 mL of 1M Tris solution (pH 6.8) (250 mM) 
 - 0,8 g of SDS (8%) 
 - 4 mL of glycerol (40%) 
 - 2 mL of β-mercaptoethanol (2%) 
 - 1 mg of Bromophenol blue (0,01%) 
 Adjust the volume to 10 mL with deionised water. Store at room temperature, 
away from light sources. 
 
Running Buffer (10x): 
 To a final volume of 1 L, add to deionised water the following: 
 - 30,3 g of Tris (250 mM) 
 - 144,2 g of Glycine (2,5 M) 
 - 10 g of SDS (1%) 
 Mix to dissolve, adjust the pH to 8.3 and the volume to 1 L with deionised water. 
 
Resolving (lower) gel solution: 
 For a final volume of 60 mL mix the following reagents: 
 
 
 
 
 
 
 
 
 
 
 10 % gel and 20% gel 
- Deionised water 17,4 mL  2,2 mL 
- 30% Acryl/0,8% Bisacryl solution 5 mL  20 mL 
- LGB (4x) 7,5 mL  7,5mL 
- 10% APS 150 µL  150 µL 
- TEMED 15 µL  15 µL 
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Stacking (upper) gel solution: 
 For a 3,5 % gel with a final volume of 60 mL mix the following reagents: 
 - 13,2 mL of deionised water 
 - 2,4 ml of 30% Acryl/0,8% Bisacryl solution 
 - 4 mL of UGB (5x) 
 - 200 µL of 10% SDS 
 - 200 µL of 10% APS 
 - 20 µL of TEMED 
 
Transfer Buffer (1x): 
 For a final volume of 1 L dissolve the following solutes in deionised water: 
 - 3,03 g of Tris (25 mM) 
 - 14,41 g of Glycine (192 mM) 
 Mix until dissolution is complete and adjust the pH to 8.3. Adjust the volume to 
800 mL with deionised water, and just prior to use add 200 mL of methanol.  
 
Tris buffered saline (TBS) 10x:  
For a final volume of 1 L dissolve the following solutes in deionised water: 
- 12,11 g of Tris (10 mM) 
- 87,66 g of NaCl (150 mM)   
Adjust the pH to 8.0, and the volume to 1 L with deionised water. 
 
TBS plus Tween (TBS-T) 10x: 
For a final volume of 1 L dissolve the following solutes in deionised water: 
- 12,11 g of Tris (10 mM) 
 - 87,66 g of NaCl (150 mM) 
 - 5 mL of Tween 20 (0,05%) 
Adjust the pH to 8.0, and the volume to 1 L with deionised water. 
 
